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Endothelin B (ETB) receptor belongs to a GPCR family, and it consists of seven 
transmembrane helices connected by three extracellular and intracellular loops. ETB 
receptor’s main function is vasodilation, thus the receptor is involved in diseases 
affecting the vasculature. Therefore, ETB targeting drugs have been a major topic in 
drug discovery and design. Several drugs have been developed, with two of them 
being bosentan and K-8794. Bosentan is an antagonist targeting both ETA and ETB 
receptors, while K-8794 is bosentan’s high affinity analog (150 nM) targeting 
selectively to ETB receptor. In this current investigation, the main goal was to explore 
and understand the mechanistic basis of bosentan and K-8794 binding to ETB receptor 
embedded in POPC, DPPC, POPE and DMPC membrane environments. To achieve 
this, a series of long-range molecular dynamics (MD) simulations were carried out. 
The trajectories from the simulation outputs were analysed for the receptor’s 
structural stability (RMSD, RMSF, Rg, H-bond). Moreover, essential dynamics 
analysis based on principal component analysis (PCA), binding free energy (BFE) 
estimation based on MM/GBSA approach, and dihedral angle analysis for the hotspot 
residues were carried out. According to the RMSD analysis revealed that all the 
systems have reached the equilibrium state during the last 200 ns of the MD 
simulations. The RMSF investigation reported that the most fluctuating regions of the 
receptor were the extracellular and intracellular loops. The Rg analysis showed that 
the ligand-receptor complexes maintained their overall compactness in most of the 
membrane environments. The H-bond analysis suggested that the ETB receptor 
residues Lys182, Lys273, and Arg343 formed relevant H-bond interactions with the 
two ligands and the ETB receptor. The PCA analysis showed that the ligand-ETB 
complexes were highly flexible by forming several conformations; however, the two 
ligands were restraining the receptor by disallowing any drastic helical movement. 
The BFE estimation revealed the most energy contributing (hotspot) residues – 
Lys182 and Trp336 for both bosentan and K-8794-ETB complexes. The dihedral 
angle analysis showed that both hotspot residues maintained similar conformation for 
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1.1. Cell membrane 
 Membranes are a necessary part of a living cell. Plasma membrane (PM) (also known 
as the cell membrane) creates a cover surrounding the inner part of the cell, by separating it 
and its organelles, from the outside environment. PM is also involved in selective nutrients 
and waste transfer, and signal transmission because of the embedded receptors, channels, and 
carriers. The cell membrane is mostly built out of lipids and proteins, and both have different 
functions (Lipid Bilayer Membranes - Chemistry LibreTexts, n.d.; Tien & Ottova, 2003).  
Lipids act as the main structural building blocks of the cell membrane, creating a lipid 
bilayer membrane (LBM). The bilayer is a fluid-like substance, and consists of two layers of 
lipid molecules, making it easy for proteins and other polymers to arrange themselves around 
the membrane (Fig 1.1A). The main functions of the lipids are to protect, retain cell structure, 
and act as enzyme cofactors and electron carriers. One of the most important groups of lipids 
is phospholipids. They are biological amphiphilic chemical compounds, constructed out of 
two parts, with one being hydrophobic and the other one hydrophilic, resembling a tadpole 
(Fig 1.1B) (Lipid Bilayer Membranes - Chemistry LibreTexts, n.d.; Tien & Ottova, 2003).  
 
Figure 1.1. Phospholipid bilayer. (A) Representation of a bilayer consisting of two lipid layers, where 
the hydrophilic part of the lipid (sphere) is facing the outside of the bilayer, and the hydrophobic 
(line) – the inside. (B) Phospholipid representation, where the sphere is the hydrophilic head and the 
two lines are the hydrophobic tail (Lipid Bilayer Membranes - Chemistry LibreTexts, n.d.; Tien & 
Ottova, 2003) 
Phospholipids can have different behaviours based on their polar (hydrophilic) head, 
and the two fatty acid chain (hydrophobic) tail. The hydrophobic part can be approximately 
16 to 20 carbon atoms long. The fatty acid chains can be saturated (have no double bonds) 
and unsaturated (double-bonded). Most of the fatty acids in the bilayer are unsaturated. As 
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seen in Figure 1.1B, one of the chains has a slight kink. The particular reason for that are the 
double bonds that are mostly in cis form. This kink blocks the tight packing of the fatty acids 
and creates the liquid-like state of the membrane (Lipid Bilayer Membranes - Chemistry 
LibreTexts, n.d.; Tien & Ottova, 2003). 
Based on the hydrophilic moiety’s functional group phospholipids are classified as: 
phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), phosphatidylserines (PSs), 
and phosphatidylinositols (PIs). In the mammalian cell, the PM is made out of 65 percent 
phosphoglycerides, 10 percent sphingolipids, and 25 percent sterols. Even though the polar 
heads in phospholipids are placed in different classes, the heads can still easily pack together. 
This creates asymmetry in the cell (Shahane et al., 2019; Tien & Ottova, 2003) Asymmetry is 
an important factor for cell viability, and the loss of it can induce apoptosis (cell death) (Tien 
& Ottova, 2003). For example, a plasma membrane of the red blood cell is constructed out of 
phospholipids consisting of lipid polar heads from several classes. The extracellular side of 
the bilayer (outer leaflet) is of PCs, while the intracellular (inner leaflet) is of PSs and PIs 
(Tien & Ottova, 2003). In other cells, the inner part of the membrane can also be of PEs. 
However, PS phospholipid mostly occupies the intracellular leaflet of the cell (Shahane et al., 
2019). The PCs are 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC), sphingomyelin and glycosphingolipids. PEs are 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) and 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPE). Further, PSs can be 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
L-serine (POPS) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) (Shahane et al., 
2019).  
The following text discusses some of the most used membranes in computational and 
experimental models, consisting of the previously mentioned phospholipids. Overall, PC is 
the most abundant phospholipid class in the membrane of an animal cell. As mentioned 
before, PCs are mostly found in the extracellular leaflet of the membrane (Shahane et al., 
2019). Its member POPC is a neutral monounsaturated phospholipid with one fatty acid chain 
being saturated and the other unsaturated. The lipid can form membranes that are used for 
biologically mimetic model systems, and is found naturally and can be produced synthetically 
(Wanderlingh et al., 2017). 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) 
phospholipid is also part of the PC class. However, DMPC is a saturated phospholipid, 
meaning it does not have double bonds in one of the side chains. The following, however, is 
far less expensive (1 g costs approximately 186 EUR) when used in experimental models, 
compared to POPC (1 g costs approximately 310 EUR) (Marquardt et al., 2014). DMPC is 
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commonly used in computational models because it can be easily parameterized for most 
biomolecular force fields (Vila-Viҫosa et al., 2014). This lipid is also very stable in 
experimental settings and easy to obtain commercially (Marquardt et al., 2014). 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) is another member of the PC phospholipid 
class. DPPC is naturally present in lung surfactants, representing approximately 50 percent of 
all PCs. Studies show that DPPC and POPC are related to respiratory distress syndrome in 
infants. Ashton et al. (1992) analysed the content of PCs in infants with respiratory distress 
syndrome. They observed that infants with such disease exhibit lower DPPC percentage and 
DPPC:POPC ratio compared with the healthy subjects. Another interesting feature of DPPC 
is that it is a saturated lipid, similarly to DMPC, whereby it exhibits less fluidity and higher 
constraining ability for a signalling protein (Angladon et al., 2019). Also, DPPC has longer 
side chains than DMPC (Angladon et al., 2019). POPE is a member of the PE phospholipid 
class. This phospholipid is the most abundant of PEs. POPE is mostly found in the 
intracellular leaflet of the cell membrane (Shahane et al., 2019). Like the other phospholipids 
mentioned before, POPE is used for many different experimental membrane systems, such as 
micelles, liposomes, and more (Fattal et al., 2004; Simões et al., 2004). 
 
1.1.1. Cell membrane receptors 
For the cell to retain and perform its designated functions, as well as communicate to 
the external environment, some very important interactions are necessary. One of them is 
signal transduction. It is a process where an outer cellular signal is transferred through a 
membrane into the intracellular part, where an alteration happens. This process is mediated 
through the lipid bilayer and ligand-binding receptors’ (also known as cell surface receptors) 
interactions. The receptors are transmembrane, meaning that they are placed into the 
membrane and extending across it. There are many receptors in a cell and they have very 
high specificity regarding certain cells (Yeagle, 2016; Tien & Ottova, 2003). All of the 
receptors are placed in three major receptor classes: ion channel-linked receptors, enzyme-
linked receptors, and G protein-coupled receptors (9.1C: Types of Receptors - Biology 
LibreTexts, n.d.).  
Ion channel-linked receptors are large receptors with several subunits, and with ligand 








to pass in and out of 
the cell (Bylund, 2014). For example, acetylcholine, gamma-aminobutyric acid, and glycine 
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are ligands binding to the channel-linked receptors. These ligands are highly present in 
neurons and are mostly called neurotransmitters (Alexander Yi & Jan, 2002).  
The second class is the enzyme-linked receptors. As the name suggests these 
receptors are associated with a specific enzyme. These receptors have an extracellular 
binding domain for ligand binding purposes and an intracellular part for enzyme binding. 
Unlike other receptor classes, they have only one transmembrane helical region (Litalien & 
Beaulieu, 2011; Waller & Sampson, 2018). Most of the associated enzymes are protein 
kinases, wherefore the receptors are placed in five groups: receptor tyrosine kinase (RTK), 
tyrosine phosphatase, tyrosine kinase-associated receptors, receptor serine-threonine kinase, 
and receptor guanylyl cyclase (Waller & Sampson, 2018). These receptors act upon 
transferring signals when a ligand binds to the extracellular N-terminal domain and actives 
the intracellular enzyme bound (Bylund, 2014). Enzyme-linked receptors are involved in cell 
apoptosis, differentiation, division and growth, as well as immune response, inflammation, 
and tissue repair (Alberts et al., 2002). 
Lastly, the third class of membrane receptors is G protein-coupled receptors (GPCRs). 
This receptor class is one of the most diverse receptor classes, including such receptors as 
secretin, rhodopsin, dopamine, serotonin, and many more. GPCRs participate in a large 
number of vital signalling functions. Because of such variety, they are also the most studied 
type or receptors for drug research and design (Yeagle, 2016; Tien & Ottova, 2003). In the 
following chapter, the structure, function, and clinical relevance of GPCRs are described 
more in-depth.  
 
1.2. G protein-coupled receptors 
 Since long ago the fascination surrounding membrane receptors has been remarkable 
in the scientific community. However, despite the fact that nowadays these receptors are one 
of the key players in the medical field, the initial idea that there may be receptors that are 
embedded into a membrane and can both locate and transmit signals, was hugely frowned 
upon. Nonetheless, later on, it was proven that such a receptor does exist. They were called G 
protein-coupled receptors (GPCRs) also known as seven transmembrane receptors 
(Lefkowitz, 2013).  
GPCRs consist of seven α-helices that are looping partly in and out of the cellular 
membrane. These are called transmembrane (TM) helices, while the “middle” part is 
submerged in between the membrane, the N-terminus positioned on the outside of the 
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membrane and the C-terminus – in the cell. The helices are connected by three extracellular 
and three intracellular loops (ECL and ICL respectively), thus creating a tube-shaped tertiary 
structure, with the middle part being hollow for effector binding purposes (Katritch et al., 
2013; Latorraca et al., 2017; Rosenbaum et al., 2009). Overall, most of the GPCRs consist of 
310 to 470 residues. Some GPCRs have a very long N-terminus region, which places them in 
certain classes. G protein (guanine nucleotide regulatory protein) binds towards the C-
terminal side of the intracellular region of GPCRs creating a ternary complex, hence the 
name (Mirzadegan et al., 2003; Palczewski, 2006).   
Approximately 3 % of the human genome consists of GPCRs, which are one of the 
biggest and most diverse superfamilies of receptors in eukaryotes. These receptors contribute 
to a large number of different intracellular responses, such as molecular transport, light 
conversion and detection, and several more, by binding many different molecules and 
effectors, including lipids, protons, drugs, hormones, and neurotransmitters (Hanlon & 
Andrew, 2015; Satagopam et al., 2010). Most of the structural deviations between the GPCR 
family members are related to the extracellular and intracellular loops, and ligand-binding 
regions. From the intracellular perspective, the major structural differences between inactive 
and active receptor states are observed in the interaction between the glutamic acid/aspartic 
acid-arginine-tyrosine (E/DRY) motif of transmembrane helix 3 (TM3) and glutamate of 
transmembrane helix 6 (TM6), which stabilizes the inactive state (Rosenbaum et al., 2009). 
GPCRs can change its structure to become active in both ligand-bound and unbound states. 
However, it is more likely that with agonistic effector bound, the structural changes will 
become more drastic. Upon activation, a large outward movement away from the 
transmembrane bundle is observed in the intracellular end of TM6. This part of the helix also 
moves closer to the transmembrane helix 5 (TM5) of the receptor, creating a cavity. That is 
when the G protein C-terminus binds to the receptor and also stabilizes it, continuing by the 
closure of the extracellular loops over the effector binding site (Congreve et al., 2020; 
Rosenbaum et al., 2009). While G protein binds to the cytoplasmic part of the receptor, 
ligands bind, for example to the extracellular part through the N-terminus or the loops of the 
receptor in a hydrophobic pocket, called the orthosteric binding site, in the top middle of the 
GPCRs as shown in Figure 1.2 (Hanlon & Andrew 2015; Katritch et al., 2013; Latorraca et 




Figure 1.2. Schematic GPCR representation. Blue rectangles (helices) and strings (loops) represent 
the GPCR protein, while the green horizontal spheres and lines represent the cellular membrane. The 
GPCR is embedded partly into the membrane while its loop region extends towards both intra- and 
extracellular regions. An effector, in this case, an allosteric ligand (orange sphere) binds to the outside 
of the receptor (allosteric binding site), while the orthosteric ligand (orange triangle) binds to the 
middle top (orthosteric binding site) of the GPCR (Latorraca et al., 2017; Rosenbaum et al., 2009). 
Generally, G protein-coupled receptors have two effector binding sites that are called 
orthosteric and allosteric. The former is surrounded by the highly conserved tryptophan of the 
TM6 and the extracellular loop 2 (ECL2). The residues that interact with the orthosteric 
ligand are mostly in TM3, TM5, TM6, and transmembrane helix 7 (TM7) (Chan et al., 2019, 
Rosenbaum et al., 2009). It is also stated by Chan et al. (2019) that the residues involved in 
the binding of ligands are also seen in transmembrane helix 2 (TM2) and the extracellular 
loops. Because it is the traditional binding site, most of the GPCR targeting drugs bind to the 
orthosteric binding site. It is so because the ligand does not need to completely penetrate the 
membrane since the binding pocket is wide open and easier to locate (Chan et al., 2019)  
Apart from the orthosteric binding site, there is a different way for an effector to bind 
to the GPCR. It is called an allosteric binding site (Figure 1.2). There are several such sites 
around the protein. These sites are further away from the binding pocket, thus mostly binding 
to the outside of the receptor. When an effector binds to an allosteric site, it can regulate the 
protein and help to modulate the orthosteric site, by either negative-allosteric modulation 
(stopping signalling by an agonist) or positive-allosteric modulation (promoting signalling by 
an agonist) (Chan et al., 2019; Congreve et al., 2020). Chan and their team (2019) have 
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observed that effectors may bind allosterically to the surface of the ELC2, TM helices, and 
the TM helices in the centre of the bilayer, and the intracellular region. However, they have 
also stated that some of the allosteric binding sites may not be suitable for, for example – 
drug discovery, unlike the orthosteric site. The effector that binds to the GPCRs creates 
different structural changes. Upon which the activated G protein sends signals activating 
several biochemical reactions within the cell. Thus, it is very important to know whether the 
effectors target the allosteric or orthosteric binding site of the GPCRs. 
 
1.2.1. Classes of GPCRs 
GPCRs are found in not only humans but also bacteria, fungi and animals. It is stated 
that over 800 GPCRs are found in humans, 700 in zebrafish, 1000 in Caenorhabditis elegans, 
1300 in mice, 200 in Drosophila, 50 in Dictyostelium and around 12 in a few species of yeast 
(Munk et al., 2019).  
The receptors are classified based on their sequence, structural similarities, 
evolutionary homology, common ligands and function. Overall GPCRs are divided into six 
classes: Class A, Class B, Class C, Class D, Class E and Class F (Satagopam et al., 2010). 
However, in mammals GPCRs are divided into classes of four: rhodopsin (class A), 
secretin/adhesion (class B/B2), glutamate (class C) and Frizzled/Taste (class F). In some 
cases class B is sub-divided into two classes as class B and B2, making the whole 
mammalian GPCRs consisting of five classes instead of four (Krishnan et al., 2012).  
Class A or rhodopsin class is the biggest class of GPCRs, and it is believed to be the 
most likely candidate for the “mother model” of all GPCRs. The class consists of 55 families 
and 640 subfamilies (Satagopam et al., 2010). Class A includes receptors for a wide variety 
of peptides, hormones, neurotransmitters, lipid-like substances and light. Most of the Class A 
receptors are involved in smell and vision. The highest amount of rhodopsin protein found is 
in the bovine retina (Palczewski, 2006). Taken up 80 % of all of the GPCRs, it is the most 
researched family regarding therapeutics (Davies et al., 2007; Satagopam et al., 2010).  
Class B/B2 or secretin/adhesion class consists of 6 families and 16 subfamilies 
(Satagopam et al., 2010). The Class B receptors bind large lipids such as secretin, which is 
from the glucagon hormone family and is involved in the cAMP-mediated signalling 
pathways (Davies et al., 2007). Both Class B and Class B2 have very long N-terminus 
domain, with many so called adhesion domains (Watkins et al., 2012) 
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Class C or glutamate class consists of 4 families and 41 subfamilies (Satagopam et al., 
2010). It is also called the metabotropic glutamate receptor class or mGluRs. Similarly to 
Class B/B2 it also contains a large extracellular N-terminus domain. This class of receptors 
are activated through an in the indirect metabotropic process (Davies et al., 2007).  
Class F or Frizzled/Smoothened class has 2 families and 11 subfamilies (Satagopam 
et al., 2010). This class is the smallest one, but is very important in the hedgehog signalling 
pathway, and is a key regulator of development of an animal organism (Davies et al., 2007). 
 
1.2.2. GPCR behaviour in the membrane environment 
 Since GPCRs are proteins inserted in the cell membrane, they have important and 
necessary interactions with the lipid bilayer. Those interactions are needed to perform protein 
designated functions. One of the protein-lipid interactions is called protein lipidation. It is a 
process where hydrophobic lipids bind to the receptor. Another one is how lipids place 
themselves in the cell membrane, for the purposes of affinity and localization of signalling 
proteins (Escribá et al., 2007). It is reported that bilayer organization is related to several 
diseases affecting GPCRs (Manna et al., 2019). Therefore, the GPCR behaviour in the 
phospholipid bilayer has been studied quite thoroughly, using synthetic lipid membrane 
systems. Two related studies will be discussed next. 
 Firstly, a computational study surrounding the adenosine A1 receptor (A1AR), which 
is part of the GPCR family, and membrane interactions was carried out by Bhattarai et al. 
(2020). The A1AR is related to such diseases as cardiomyopathy, neuropathic pain and renal 
disease, and several more (Bhattarai et al., 2020; WikiGenes - Adora1 - adenosine A1 
receptor, n.d.). Therefore, it is an important target for the drugs treating these diseases. The 
study was carried out by inserting the signalling protein in its two states (active and inactive) 
with and agonist or an antagonist, respectively, into the POPC membrane and simulating the 
ligand-protein-lipid interaction using Gaussian accelerated molecular dynamics (GaMD). 
Bhattarai and the team revealed that in both active and inactive state the ligand interaction 
with the protein remained stable. However, the fluctuations of the TM6 and TM5 intracellular 
region seemed to be much higher in the active state than inactive, explaining the membrane 
and lipid interaction importance for the fluidity. They also reported that the inactive state of 
the receptor interacted more with the POPC lipids in the outer part of the bilayer. However, 
the phospholipid head group heavily coordinated towards four lysine residues of the 
intracellular part of the TM6 in the A1AR active state to stabilize the receptor. Hence, their 
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study revealed that GPCRs have different interactions with phospholipid bilayer depending 
on the activation state. 
 Secondly, a study by Angladon et al. (2019) was conducted regarding a different 
GPCR protein called μ opioid receptor (μOR). This receptor is related to several mood 
disorders and inflammatory bowel diseases, and mediates the effects of opioids (Angladon et 
al., 2019; Lutz & Kieffer, 2013; Philippe et al., 2006). In their Molecular Dynamics (MD) 
simulation study, they used DPPC and POPE lipid membranes, with POPC being used as a 
reference model. They reported that the biggest change in protein conformation was at TM5, 
where it exhibited large values of the tilt angles. Even though they reported similar changes 
in all three lipid systems, it seemed that the largest TM5 tilt value was observed for the 
POPC, followed by the DPPC and POPE lipid systems. They have also reported how 
differently the lipid membrane interacts and changes the conformation of the μOR: for all 
three membranes, the most interactive helices were transmembrane helix 1 (TM1), 
transmembrane helix 4 (TM4) and TM5. However, some helices preferred to interact 
differently among the membranes: TM1, TM5 and TM6 especially with POPC, TM5, TM6 
and TM7 with POPE, TM4 and TM6 with DPPC. In summary, they concluded that DPPC, 
being saturated unlike POPC and POPE, can create more contacts with receptor helices. 
While POPC and POPE that are unsaturated, can introduce more flexibility to the GPCR’s 
structure. 
 
1.2.3. Clinical relevance of GPCRs 
 As mentioned previously GPCRs are abundant, and these receptors are involved in 
every step of the way of the development of an organism (Hanlon & Andrew, 2015). GPCRs 
are very sensitive to responding to sensory stimuli, such as light, odour and taste.  They are 
also very important in the mediating hormones’ effects (Satagopam et al., 2010). Since 
GPCRs are involved in a huge variety of intracellular signalling cascades, mutations of these 
receptors in humans are frequent and can lead to several diseases. For example, hormonal 
mutations or blockage of signalling caused by mutations can be the root cause of onset deaf, 
blindness, vascular diseases, endocrine disorders and many more, which are related to 
hormonal mutations or blockage of signalling (Hanlon & Andrew, 2015). This further 
supports the GPCRs' relevance in medicine and drug development. 
As of now about 34 % of drugs bind to GPCRs and account for about 180 billion US 
dollars (149 billion euros) profit for pharmaceutical companies annually (Congreve et al., 
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2020; Hauser et al., 2018). Most of the drugs created today bind to the orthosteric binding site 
and act as inhibitors (antagonists) or activators (agonists), which will be discussed in the later 
chapters. For the early development of most of the GPCR drugs, the high-resolution 
structural information of the receptors was not available. However, over time some important 
GPCR structures have been successfully determined and more unique receptors and ligands 
have been found, which has created even more opportunities for the design and creation of 
new medications (Hauser et al., 2017).    
 
1.3. Endothelin 
 After the discovery of endothelium-derived relaxing factor back in 1980, five years 
later the existence of vasoconstricting factor was reported. However, the research for the 
vasoconstricting factor began only in 1987 by Masaki and the team, which also led to believe 
that the factor is actually a peptide. Thus the research had led to the discovery of endothelin 
(Masaki, 1998).  
Endothelin (ET) is a polypeptide consisting of 21 amino acids with four cysteine 
residues that are interlinked to form two disulfide bridges (Figure 1.3 A) ET functions as a 
blood vessel tightening agent and also as a blood pressure raiser. However, it can also act as a 
vasodilator. The polypeptide is encoded by the human ET gene. Structurally the hydrophobic 
C-terminus and N-terminus of the peptide have slightly different functions: amino acids in 
the C-terminus bind to the receptor, while the N-terminus acts as a determinant for the 
binding affinity (Khimji & Rockey, 2010). 
As stated by Masaki et al., (1998), endothelin was found in cultured bovine 
endothelial cells. However, after further analysis of the human ET gene, it was discovered 
that there are two other ET-like peptide genes. These peptides are called endothelin-2 (ET-2) 
(Figure 1.3 B) and endothelin-3 (ET-3) (Figure 1.3 C), thus renaming the first discovered ET 
as endothelin-1 (ET-1) (Masaki, 1998). This actively demonstrates that endothelin in total has 
three isoforms and they differ from each other by two (Trp and Leu) to six amino acids (Leu, 














Figure 1.3. Endothelin structure in IUPAC representation. (A) endothelin-1, (B) endothelin-2, (C) 
endothelin-3 (Endothelin-1 | C109H159N25O32S5 - PubChem, n.d.; Endothelin 2, human | 
C115H160N26O32S4 - PubChem, n.d.; Human endothelin-3 | C121H168N26O33S4 - PubChem, 
n.d.).    
The three isoforms are produced from different human organs and cells. Endothelin-1 
is mainly sourced from endothelial cells, but can also be found in the cardiomyocytes, 
vascular smooth muscle cells as well as macrophages and monocytes, airway epithelial cells, 
fibroblasts, brain neurons, enteric glial cells and many other cells. Endothelin-2 is mostly 
found in the intestine, kidney, ovary, vasculature, heart and lung cells. Unlike ET-1 and ET-2, 
endothelin-3 is not synthesised by human endothelial cells, but is expressed in the adrenal 
gland, glial cells, and neuronal stromal cells. It also plays an important role in cellular 
proliferation and development, as well as mediates release of vasodilators (Barton & 
Yanagisawa, 2008; Davenport et al., 2016; Masaki, 1998).  
The synthetic pathway of endothelin is very complex as seen in Figure 1.4. For the 
synthesis of ET-1, the pathway starts by the transcription and translation of the 
preproendothelin-1 mRNA where the preproendothelin-1 is synthesized. Preproendothelin-1 
is a 203 amino acid peptide. This peptide undergoes proteolysis, a breakdown into shorter 
peptides, with the help of furin-like protease. This process creates big endothelin-1, which is 
a chain of 37 to 41 amino acids; however, this type of ET is biologically inactive. Big 
endothelin-1 then undergoes cleavage with the aid of membrane-bound zinc metalloprotease 
called endothelin-converting enzymes (ECEs) and also the non-ECE metalloproteinase, 
chymase and vascular smooth muscle cell (VSMC) chymase. This produces the biologically 
active endothelin-1. The same pathway is also assumed to be followed by both ET-2 and ET-
3. However, for both ET-2 and ET-3, only the ECEs are active during the big endothelin 




Figure 1.4. Endothelin synthesis pathway. The asterisk (*) represents number 1, 2 or 3 for either ET-
1, ET-2 or ET-3 (Barton & Yanagisawa, 2008). 
1.3.1. Endothelin receptors 
Endothelins participate in a wide range of physiological functions in the human body. 
Therefore these peptides function through binding to their highly selective receptors in an 
extremely complicated process. One of the steps in the process is binding its C-terminal tail 
deeply into the receptors’ orthosteric binding pocket (Houde et al., 2016).  
The receptors are called endothelin A (ETA) and endothelin B (ETB). ETA is a non-
peptide selective receptor, while ETB is peptide-selective. Both of these receptors belong to 
the GPCR family of Class A or rhodopsin class, whose structure includes seven 
transmembrane helices. The receptors are constructed out of approximately 400 amino acids 
in total, with the transmembrane domains made out of 22 to 26 hydrophobic amino acids 
(Khimji & Rockey, 2010). Interestingly enough, in the paper of Davenport et al. (2016), it is 
stated that the genes encoding peptides are an innovation that has evolved strictly in the 
vertebrates such as jawless vertebrates, cartilaginous vertebrates and bony vertebrates. 
Endothelin A and endothelin B in human are expressed slightly differently between 
the organs. ETA is comprised of 427 amino acids as described in the UniProt database under 
entry code P25101 and it is 63 percent similar to the endothelin B in human (Davenport et al., 
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2016). Generally, endothelin A receptor is less abundant than ETB and can be mostly sourced 
from the smooth muscle cells, myofibroblasts, cardiomyocytes, hepatocytes, neurons, 
osteoblasts, keratinocytes and adipocytes (Khimji & Rockey, 2010). Endothelin B unlike ETA 
has a slightly longer peptide sequence comprised of 442 amino acids. Compared to ETA the 
receptor has a far longer N-terminus. Regarding the binding of an effector, TMs that 
contribute are TM1 to TM3 and TM7, as well as the related extracellular loops. 
Transmembrane helices TM4 to TM6 and their ECLs are involved in the selectivity of the 
receptor binding, and C-terminal participates in the signalling (Mazzuca & Khalil, 2012). 
These actions are important for activation of the receptor. ETB can be located in the same 
cells as the ETA mentioned before, however ETB can also be spotted in the endothelial cell 
and renal collecting-duct cells (Khimji & Rockey, 2010). With respect to the organ 
distribution, ETB in the human brain represents up to 90 percent of total endothelin receptors 
(ETRs) (Davenport et al., 2016). In heart tissue, ETA comprises 60 percent of endothelin, 
while in the kidney 70 percent of ETRs are reported to be ETB. In addition, in the smooth 
muscle layer and human vasculature ETA is more abundant compared to ETB. Thus taking all 
into account, human kidney, lung, brain and liver are mostly ETB rich, whereas heart is ETA 
rich (Maguire & Davenport, 2015).  
Both ET receptors can signal via calcium-dependent and calcium-independent 
pathways (Houde et al., 2016). However, their ligand affinity differs when it comes to ET-1, 
ET-2 and ET-3. Only ET-1 and ET-2 bind to ETA and signal via it, while all three ET 
isoforms bind to ETB (Davenport et al., 2016). Additionally, as reported by Shihoya et al. 
(2017), when ET-1 activates the ETB receptor, it induces conformational changes to the TM6 
and TM7, causing their extracellular regions to move inwards by 4 Å, where after the 
following conformational changes in the core and the TM7 cytoplasmic part cause the TM6 
intracellular region to move outwards. The receptors also express different types of activities 
from each other. When ETA is activated, it functions as a narrower of blood vessels. On the 
contrary, ETB receptor upon activation releases vasodilators and expands the blood vessels, 
and the receptor may even act as inhibitor for both cell growth, and vascular constriction in 
the blood vessel system (Kawanabe & Nauli, 2011). Because of these opposite effects to 
those of the ETA receptor, ETB-selective agonists have been studied as vasodilator drugs for 
the improvement of tumour drug delivery, as well as for the treatment of hypertension, 
chronic heart failure and more (Davenport et al., 2016; Kawanabe & Nauli, 2011). Targeting 
the ETB signalling system may be an important step towards the treatment of related human 
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diseases. For example, as stated by M. Houde et al. (2016) about the relevance of ET-1 and 
its receptor interactions: 
A better understanding of how ET-1 is synthesized and how ETA and ETB receptors 
interact could help design better pharmacological agents in the treatment of 
cardiovascular diseases where targeting the ET-1 system is indicated (p. 144). 
 
1.3.2. Endothelin related diseases and treatment 
1.3.2.1. General receptor-targeting drug types 
 Generally, there are three types of receptor-targeting drugs: agonists, antagonists and 
allosteric modulators. The agonist and antagonist types are characterized based on their 
biological response (%) for a given tissue. Between the two, the drug type with the highest 
response is an agonist; while the lowest response is observed in the antagonist binding, where 
it shows no response at all and blocks the effect of an agonist (Kenakin, 1987). The two drug 
types bind to the receptor mimetically to the natural ligand (Kenakin, 1987).  
Receptor agonists are classified into three categories: full, partial and inverse. A full 
agonist when bound activates the receptor to its fullest. A partial agonist acts similarly but 
with lower efficacy, producing a non-maximal response. An inverse agonist binds like a full 
agonist but expresses inhibitory effects and exhibits a complete negative response (Kenakin, 
1987; Pharmacological Glossary | Tocris Bioscience, n.d.).  
Receptor antagonists, on the contrary, do not activate the receptors when bound. 
Hence and antagonist inhibits the receptor’s activity and prevents other molecules from 
binding and activating the receptor. Antagonists are classified into two categories: 
competitive and non-competitive. Competitive is the most well-known type of antagonists; it 
acts as an inhibitor. On the other hand, a non-competitive antagonist binds to the allosteric 
binding pocket instead of the usual orthosteric site and prevents the activation of the receptor 
(Pharmacological Glossary | Tocris Bioscience, n.d.).  
 Allosteric modulators, unlike agonists and antagonist, bind to the allosteric site, which 
is distinct from the orthosteric site. This type of drug can regulate the protein and help to 
modulate the orthosteric site. Additionally, when bound it induces conformational changes 
and increases affinity of a ligand bound to the orthosteric pocket. Allosteric modulators are 
classified into positive and negative. The former class of modulators promotes signalling by 
an agonist and increases its affinity, while latter stops signalling by an agonist and decreases 
its affinity (Pharmacological Glossary | Tocris Bioscience, n.d.). 
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1.3.2.2. Diseases and treatment 
 Out of the three ET isoforms, ET-1 is the most abundant one, and thus the most 
researched isoform. Since ET-1 is both ETA and ETB selective, most of the endothelin-related 
diseases and their treatment are associated with the ET-1 system (Davenport et al., 2016). 
Several clinical studies have demonstrated that endothelin is involved in diseases such as 
pulmonary arterial hypertension (PAH), arterial hypertension (AH), renal diseases, allograft 
rejection, diabetes and insulin resistance, cancer, heart failure, and atherosclerosis (Barton & 
Yanagisawa, 2008). 
 Most endothelin-related diseases are affecting the vasculature (Barton & Yanagisawa, 
2008; Kawanabe & Nauli, 2011). The most well-known of such diseases is called pulmonary 
arterial hypertension (PAH). PAH is a rare disorder that is progressive and shows signs of 
elevated blood pressure (hypertension), in the arteries of the lungs (pulmonary artery) 
(Kawanabe & Nauli, 2011; Schneider et al., 2007). The cause of the disease is unknown. 
People mostly affected by this disorder are women of ages 30 to 60, and people with 
disorders such as connective tissue disease, heart failure and HIV infection (Barton & 
Yanagisawa, 2008; Schneider et al., 2007). The late prognosis of patients with PAH leads to 
poor treatment outcomes, and most patients die within two to three years after the diagnosis 
was made. The first successful treatment was vasodilator therapy using calcium channel 
blockers or prostaglandin administration. However, it proved to cause side effects and the 
efficacy was very limited, especially for patients with non-vasoreactive PAH (Schneider et 
al., 2007). Therefore, other pharmacological options were being considered, one of them 
being ET receptor antagonists (Iglarz et al., 2015). Regarding ET and the disease in general, 
ET-1 is very important for normal blood circulation in the lung artery. In people with normal 
blood pressure, the levels of ET-1 are stable. However, patients affected with PAH exhibit 
high levels of ET-1 in the pulmonary artery (Kawanabe & Nauli, 2011; Schneider et al., 
2007). It has also been observed that high levels of ET-1 cause vascular remodelling 
(Kawanabe & Nauli, 2011). This discovery led to the belief that there might be an 
overproduction or decreased clearance of the circulating ET-1. It was shown then that the 
PAH patients exhibited regular ET-1 clearance but showed high production of ET-1. 
Therefore, this proved that one of the main causes for PAH is the overproduction of ET-1, 
due to the increased ET-1 mRNA expression in the pulmonary vascular endothelial cells 
(Kawanabe & Nauli, 2011; Schneider et al., 2007). Overproduction of ET-1 leads to 
overexpression of ETA and ETB. Both receptors are very important for retaining normal 
pulmonary vascular tone in a hypoxic environment, which means that any changes in ETA or 
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ETB receptor expression can cause PAH (Mazzuca & Khalil, 2012). For example, Ivy et al. 
(2005) in their study discovered that ETB receptor downregulation in rats can cause PAH. On 
the contrary, ETA receptor increase can also lead to the development of PAH as reported by 
Takahashi et al. (2001) who mention that ETA expression can become upregulated two-fold. 
This suggests that ET-1 and endothelin-receptor targeting drugs could be good alternatives 
for PAH treatment.  
As mentioned before, the previously tested drugs displayed low efficacy and related 
side effects. Therefore, there was a need for improved medication options. Several ET 
receptor antagonists have been developed that can help to slow down the further development 
of PAH (Schneider et al., 2007). The first of its kind ET receptor antagonist was called 
bosentan (Figure 1.5).  
 
Figure 1.5. 2D chemical structure of bosentan (Bosentan | C27H29N5O6S | ChemSpider, n.d.). 
It became the first to be approved as a PAH targeting medication by U.S. Food and 
Drug Administration (FDA) back in 2002, specifically for the patients that exhibit symptoms 
in the New York Heart Association (NYHA) and World Health Organisation (WHO) 
functional class II and IV. It is also the most utilized drug to date (Barton & Yanagisawa, 
2008; Kawanabe & Nauli, 2011; Mazzuca & Khalil, 2012). Bosentan is a non-peptide 
sulphonamide with mixed ETA and ETB inhibitory activity. It acts by binding to both 
endothelin receptor types and blocking them, thus inhibiting the effects of endothelin-1. The 
drug has been shown to be effective in two trials with a survival rate of between 96 and 89 
percent after one and two years respectively, with the orally administered dose of 125 mg 
twice a day (Kawanabe & Nauli, 2011; Mazzuca & Khalil, 2012; Schneider et al., 2007). 
Bosentan has a vasodilatory effect and can inhibit pulmonary arterial smooth muscle cell 
proliferation and prevent pulmonary vasculature remodelling, as well as help to treat digital 
ulcers of systematic sclerosis (Kato et al., 2020; Kawanabe & Nauli, 2011). In a very recent 
study by Kato et al. (2020) regarding bosentan, it was discovered that besides the 
involvement of smooth muscle cells, endothelial cells (ECs), macrophages and fibroblasts in 
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pulmonary vasculature, and bone marrow (BM) stem or progenitor cells can contribute to the 
development of PAH. They reported that the regulation of BM-derived ECs and BM-derived 
macrophages by bosentan in the lungs can help to control PAH in mice. More specifically 
BM-derived cells might have been promoted under upregulation of nitric oxide synthase 3 
(eNOS) when ETB blockage was active. Also through blocking the ETA receptor, macrophage 
expression was downregulated. 
 Other medications approved by the FDA for the PAH patients exhibiting the WHO 







Figure 1.6. 2D chemical structures of (A) ambrisentan, (B) enrasentan and (C) sitaxentan 
(ambrisentan | C22H22N2O4 | ChemSpider, n.d.; Enrasentan | C29H30O8 | ChemSpider, n.d.; 
sitaxentan | C18H15ClN2O6S2 | ChemSpider, n.d.). 
However, unlike bosentan that is binding non-selectively to the ETRs, all three drugs 
are ETA selective antagonists. For example, ambrisentan seems to be effective at the dosage 
of 5 to 10 mg when taken daily, showing improved one-year survivability. All three drugs 
reduce pulmonary artery pressure and help to control vascular remodelling (Kawanabe & 
Nauli, 2011; Mazzuca & Khalil, 2012; Schneider et al., 2007). 
 On the other hand, medications are usually paired with several unwanted adverse 
effects. Bosentan is no exception. Its adverse effects include hepatotoxicity, edema, 
teratogenicity in pregnant women and several more (Belge & Delcroix, 2019). The latter is a 
common adverse effect among all ETR targeting drugs. Therefore a new ET receptor 
antagonistic drug was developed called macitentan (Figure 1.7).  
 




Macitentan is a non-ETR selective antagonist. This drug was approved as a viable 
option for PAH treatment back in 2013 by FDA and European Medicines’ Agency (EMA) at 
the dose of 10 mg taken orally daily (Bedan et al., 2018). In the studies by Bedan et al. (2018) 
and Iglarz et al. (2015), macitentan is illustrated as having a far greater and more prolonged 
ET receptor binding occupancy compared with bosentan. Therefore, macitentan can better 
block the ETRs despite the high prevailing ET-1 concentration. Regarding the binding of 
macitentan, Gatfield et al. (2012) suggested that since the drug differs greatly from the 
structure of bosentan, it most likely has a different binding mode at the ET receptors. 
Moreover, studies by both Bedan et al. (2018) and Iglarz et al. (2015) revealed that 
macitentan, unlike bosentan, has better tissue penetration and distribution properties. 
Treatment by macitentan results also to lower morbidity, and the mortality risk reduced to 50 
percent. Regarding some of the adverse effects of bosentan, macitentan greatly reduced the 
chance of developing edema (Maguire & Davenport, 2015). However, regarding the risk of 
teratogenicity in pregnant women, macitentan showed no difference compared to bosentan 
(Bedan et al., 2018). 
 Apart from the PAH disease, ET-1 and ETRs are involved in other disorders as well. 
One such reported disorder is sickle cell disease (SCD). SCD is characterized by an inherited 
unique mutation in the β-globin gene that is related to haemoglobin. This leads to normal 
blood flow blockage by red blood cells related to the modification of their shape. The 
reported ET-1 involvement is illustrated by Koehl and their team (2017). They mention that 
in patients with SDC ET-1 system is being activated and the concentration of ET-1 is high 
compared to healthy subjects. This leads to a prominent adhesion of neutrophils to 
endothelium by the functioning ETB receptors. The high concentration of active neutrophils 
may interact with several vascular cells, and cause decreased blood flow and endothelial 
injury.  
Another disease that is related to ET system is hepatopulmonary syndrome (HPS). 
HPS is described by dilatation of blood vessels in the lungs and as a complication of a liver 
disease (scarring of the liver or cirrhosis). This disorder occurs in 5-32 percent of patients that 
have such a liver disease (Hepatopulmonary Syndrome - NORD (National Organization for 
Rare Disorders), n.d.). Ling et al. (2004), has reported that ET-1 and ETB receptor has a 
relevant role in the experimental HPS (a model where the physiological abnormalities are 
reproduced in animals similarly to human disease). Ling and the team reported that ET-1 
concentration is enhanced by ETB receptor activation in the pulmonary microvascular 
endothelium while HPS is still developing. They also discovered that selective ETB 
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antagonism helped to improve HPS. Therefore, these reported findings may have relevance to 
the human disease, because in human patients with pulmonary microvascular dilation ET-1 
levels were also elevated compared to healthy subjects as reported by Koch et al. (2012). 
   Chronic heart failure (CHF) or also known as congestive heart failure is another 
disease that is highly researched. Similarly to PAH, in patients that exhibit CHF, ET-1 levels 
are highly increased, two to three times higher than normal, due to the minimized clearance 
of ET-1 (Khimji & Rockey, 2010; Schneider et al., 2007). When normal cardiac function is 
impaired, the human heart starts to fail showing unusually high levels of endothelin tissue, 
while in the healthy human heart normal levels of ET contribute to inotropy, chronotropy, 
and arrhythmogenesis, and contractile function of cardiac myocytes (Barton & Yanagisawa, 
2008, Schneider et al., 2007). ET-1 also plays a big role in the ventricular remodelling of the 
heart. Interestingly enough, ET-1 overexpression mostly happens in the left ventricular, 
alongside with the overexpression of the ETA receptor. On the contrary, the ETB receptor is 
downregulated (Rich & McLaughlin, 2003).  
Many clinical trials have been carried out to study the endothelin receptor blockers as 
a medication for CHF (Barton & Yanagisawa, 2008). For example, RITZ (The Randomized 
Intravenous TeZosentan) trial underwent examination of the usage of tezosentan (Figure 1.8). 
 
Figure 1.8. 2D chemical structure of tezosentan (tezosentan | C27H27N9O6S | ChemSpider, n.d.). 
However, the outcome of the trial was mostly negative as it showed no significant 
difference in the primary endpoint. Another such trial was REACH (Research on Endothelin 
Antagonism in Chronic Heart Failure) where the examined ET receptor antagonist was 
bosentan. However, the trial was prematurely terminated because of a risen concern over the 
elevated concentration of liver enzymes (up to 15.6 %) (Rich & McLaughlin, 2003; 
Schneider et al., 2007). Another trial that also examined bosentan’s effect on CHF was called 
ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events). The trial seemed 
to be a failure as well, as it showed no improvement. Instead, it was reported that the trial 
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subjects exhibited elevated fluid retention, edema and transaminase concentration (Rich & 
McLaughlin, 2003; Schneider et al., 2007).  
On the other hand, trials HEAT (Heart Failure ET(A) Receptor Blockade Trial) and 
EARTH (Endothelin A Receptor Antagonist Trial in Heart Failure) were demonstrating some 
promising results. The both trials examined ETA receptor antagonist darusentan (Figure 1.9).  
 
Figure 1.9. 2D chemical structure of darusentan (Darusentan | C22H22N2O6 | ChemSpider, n.d.). 
This HEAT trial showed significant improvement in cardiac index. Yet increased ET-
1 levels were reported even though the ETA receptor was blocked. Other than that, major 
concerns were raised as 4 deaths were reported. Even though the EARTH trial was initially 
giving some promising results as darusentan was well tolerated, unfortunately after 6 months 
no beneficial effects were observed, as CHF worsened and 4.7 percent of patients died (Rich 
& McLaughlin, 2003; Schneider et al., 2007).  
Additionally, Sawaki et al. (2000) researched the effects of K-8794 (Figure 1.10), an 
orally taken ETB selective antagonist, for CHF treatment administered in a CHF experimental 
model (dogs with heart failure).  
 
Figure 1.10. 2D chemical structure of K-8794 (K-8794 | Ligand page | IUPHAR/BPS Guide to 
PHARMACOLOGY, n.d.). 
Two groups were investigated: placebo (control) and K-8794 group. They reported 
that when K-8794 was taken, blood pressure decreased. However when compared to the 
placebo group the values of K-8794 group were higher. Increase in levels of systematic 
vascular resistance was also demonstrated in both groups, with K-8794 group displaying 
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higher values. They concluded that K-8794 may still help with tackling CHF by prevention of 
body fluid retention, even though the antagonist expressed disadvantages to the flow of blood 
in the experimental model.  
In sum, ET-1 and ETRs are involved in many different diseases. Apart from the PAH, 
HPS, SCD and CHF disorders, the ET-1 system is also involved in renal disease, diabetes and 
obesity (D’Orléans-Juste et al., 2019). Endothelin is also reported to have an important role in 
essential hypertension, atherosclerosis, central nervous system diseases, carcinogenesis, 
Alzheimer’s disease, and Hirschsprung's disease as presented by Kusafuka & Puri (1997), 
and many more (D’Orléans-Juste et al., 2019). In some of the diseases, several ET receptor 
targeting blockers have shown good results. However, in some of the trials, the results 
demonstrated a failure, as ETR antagonists display unwanted adverse effects (Barton & 
Yanagisawa, 2008). Nevertheless, new and improved drugs are being continuously 
developed, such as macitentan, showing lesser adverse effects. Furthermore, well-designed 
clinical studies may present a far better therapeutic potential for the new generation of drugs. 
  
1.4. Molecular Dynamics Simulation 
 In the previous chapters, Molecular Dynamics (MD) simulation was mentioned as the 
method used in the discussed lipid-receptor interaction studies. Because of its effortless 
approachability, MD simulation has become a popular approach for various studies aiming to 
understand molecular motions and interactions. MD simulation is a computer simulation 
method that incorporates Newtonian laws of motion to investigate the physical movements of 
atoms and molecules such as water, macromolecules, lipid membranes, nucleic acids and 
more complex systems of biomolecules, to reproduce the behaviour of the biological 
environment and understand the biological aspects of such systems (Miller, 1995). The 
approach was developed in the late 70s and has advanced into a far more complex method 
leveraging the super-computational power (Hospital et al., 2015).  
 MD simulation can be applied for example for studying allostery, structure prediction, 
molecular docking and drug design (Hospital et al., 2015). The latter is one of the most 
interesting topics nowadays. For example, MD simulations can simulate and reveal 
information about a biomolecule’s conformational changes that take place during ligand 
binding. By the method it is possible to spot changes in a protein, induced by the outer 
environment such as membrane, and reveal direction of movements related to folding and 
much more. The method can furthermore help to effectively understand structural stability 
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and changes in free energy (Hernández-Rodríguez et al., 2016; Hollingsworth & Dror, 2018; 
Hospital et al., 2015). 
 The actual algorithm is quite complex, but the idea is easy to comprehend. In the 
beginning, the whole simulation time must be separated into several short time steps – around 
10
-15
 seconds per step. Fortunately, biological events happen in short time scales 
(nanoseconds, microseconds), making it possible to simulate them with the available 
computational power. A molecular mechanics force field must be selected that calculates 
forces acting on each atom. Later the position and velocity of an atom must be calculated and 
updated every step using Newtonian laws of motion (Hollingsworth & Dror, 2018). Force 
field includes a combined calculation of bond angles, van der Waals and electrostatic 
interactions for parameterized molecular systems. The most popular biomolecular force fields 
used nowadays are AMBER, CHARM, GROMACS and OPLS (Hernández-Rodríguez et al., 
2016). The choice of the force field depends on the scientists themselves, and the research 
carried out. Apart from the force field, the importance of the solvent rises. The biological 
solvent is water. Therefore, before running the experiment the solvent molecules are 
necessary to add because they instigate important changes to the biomolecule. Salt ions are 
added to neutralize the system and often also to simulate the salt concentration at 
physiological conditions, whereas lipids are used to imitate cellular membranes. Thus, the 
simulation box that is used to perform the MD simulation is a model of a biomolecular 
system that consists of the biomolecule(s) in the solvent (Figure 1.11) (Hernández-Rodríguez 




Figure 1.11. The simulation box of a system comprising of the ETB receptor in complex with K-8794 
embedded in POPC membrane used for MD simulations.   
The 3D structure of biomolecular targets for the simulations are usually retrieved 
from the Protein Data Bank (PDB), which is an archive for storing the information about 
different types of biological structures (biomolecules), and their experimentally determined 
3D shapes (Berman et al., 2000). On average, MD simulations can routinely be carried out 
for systems containing ca. 100,000 atoms. However, depending on what type of computer 
hardware or MD algorithms are available, much bigger systems are also becoming feasible to 
simulate (Hollingsworth & Dror, 2018; Hospital et al., 2015). Besides that, there are many 
MD simulation (MDS) softwares to choose from such as AMBER, NAMD, CHARMM, 
GROMACS, and DESMOND to name a few. In current days, most of the mentioned 
software runs on graphic processing unit (GPU) utilization, which promises accelerated 
performance when compared to central processing units (CPU) (Hernández-Rodríguez et al., 
2016). The simulation must have a defined simulation time, which varies from picoseconds to 
milliseconds, and a frame count (how many snapshots are saved along the simulation). This 
at the end creates a trajectory. The trajectory is assembled of the system snapshots created 
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throughout the simulation run that can be superimposed over the first initial frame (initial 
system), creating a movie like an animation (Hollingsworth & Dror, 2018).  
MD simulation can reveal different types of biological and structural details. For the 
analysis of such, many different approaches can be used. The most basic method is the visual 
analysis of the trajectory, whereas more informative tools include, to name a few:  Root 
Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of 
Gyration (Rg), Clustering Analysis, Free Energy Calculations, Principal Component Analysis 
(PCA) and more (Hernández-Rodríguez et al., 2016). 
Like every method, MD simulation has its limitations. The method is very time 
consuming (Biagini et al., 2019). Especially when the simulation is set to run for 500 
nanoseconds or even more. The MD simulation can take up to days or weeks of simulation 
job time (Hollingsworth & Dror, 2018; Hospital et al., 2015). Apart from the actual 
simulation, the analyses of the trajectory can also take several hours. Importantly, one run of 
MD simulation is usually not enough to gather accurate results, because for example, MD 
simulation did not reach equilibrium. This means that several simulations of one system must 
be carried out and analysed, which can take up to weeks (Hollingsworth & Dror, 2018; 
Hospital et al., 2015). Therefore software and hardware improvements, such as GPU 
utilization, have been a major advantage regarding MD simulation (Biagini et al., 2019). 
Furthermore, free energy calculations are merely approximations and offered methods may 
be more or less superior to each other. However, at the end of the day, the most important 
aspect of MD simulation precision is the accuracy of the 3D structures analysed (Hernández-
Rodríguez et al., 2016; Hollingsworth & Dror, 2018; Hospital et al., 2015).   
 
1.4.1. Molecular Dynamics Simulation and GPCRs 
Several studies have incorporated MDS for the purpose of analysing how effectors 
interact, affect and induce structural changes to the signalling protein. The changes induced, 
however, depend on the effector structure and type (Ferruz et al., 2018; Renault et al., 2019; 
Singh et al., 2019; Yuan & Xu, 2018) In the following text several studies, of which MDS 
was used for analyses of GPCRs, will be discussed.  
Histamine H3 receptor of the GPCR family activity has been studied by Herrera-
Zúñiga and the team (2019) using MD simulation. The active state, agonist-bound and the 
inactive state, antagonist-bound to H3 receptor was simulated in the DPPC phospholipid 
bilayer system, together with the apo receptor in the active state for a comparative analysis. 
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The study revealed that throughout the simulation all ligand-bound active and inactive states 
of the receptor go through conformational changes resulting in four clusters each. While the 
apo exhibits only three. Regarding the clusters, the scientists presented that for all the 
structures the extra and intra cellular loop motion is highly flexible, especially the ECL2, 
extracellular loop 3 (ECL3), and the intracellular loop 2 (ICL2), intracellular loop 3 (ICL3). 
On the other hand, the antagonist-bound structure revealed a tilt like movement of TM1, and 
a pendulum-like rigid-body motion of TM5-TM7 and their loops, while the helices of the 
agonist-bound structure (which represents the active state) did not exhibit important 
movements. Regarding the apo structure, the flexibility of the loops is even more enhanced. 
These findings show how the absence or the presence of a ligand can affect the receptor 
structure. They also observed that the ligands interact with the orthosteric binding pocket 
residues differently through the simulation by breaking and establishing new hydrogen bonds.  
Another study has also reported MDS being a good method for understanding GPCR 
structural changes and signalling. Ichikawa et al. (2016) investigated how 14 different ligands 
(mostly agonists) of β2-adrenergic receptor (β2AR) affect the G-protein and β-arrestin bound 
active and inactive states, while embedded in the POPC membrane. During the study they 
observed that the well-known kink in helix 6 is present in the G-protein-active state. 
Similarly to the previously discussed study, high fluctuations were present in the TM3, TM5, 
TM6, TM7 and the extracellular loop 1 (ECL1), ECL2 for G protein-bound receptor. For β-
arrestin-bound receptor, structural changes were mostly visible in TM1 and TM7. When 
comparing ligand biases between G-protein and β-arrestin-bound receptor states, it appeared 
to be that the ligands chosen showed higher bias towards G-protein-bound state.  
In essence, the studies discussed here show how the chemical structure of a ligand can 
induce changes in the GPCR structure, and how throughout the time when the receptor is 
active or inactive, the non-covalent interactions between the binding pocket residues and the 
ligand changes. It is worth mentioning that ECL2 acts as a key player in stabilizing the GPCR 
receptor conformation as reported by Seibt et al. (2013), which the activity of ECL2 is also 




2. AIM OF THE STUDY 
As mentioned before, ETB receptor is widely expressed in human body. Upon 
activation it releases vasodilators and expands the blood vessels, and the receptor may even 
act as inhibitor for both cell growth, and vascular constriction in the blood vessel system. The 
receptor is involved in several human diseases, such as pulmonary arterial hypertension 
(PAH), arterial hypertension (AH), renal diseases and more. Hence, ETB targeting drugs were 
developed. However, some paired with several unwanted adverse effects (Davenport et al., 
2016; Houde et al., 2016; Kawanabe & Nauli, 2011). Additionally, it is reported that some 
receptors can behave differently in different membrane environments (Angladon et al., 2019). 
Therefore, targeting the ETB signalling system by means of different types of relevant 
computational methods can provide knowledge about the receptor and ligand interactions, 
behavioural insights when exposed to different biological environments, and may help with 
further drug development and discovery for the ETB receptor-related medical disorders. 
However, there are far too few studies exploring the interaction between ETB receptor and its 
ligands. Therefore, it may be interesting to explore the behaviour of ETB-ligand complexes, 
when embedded in the well-known membrane environments: POPC (1-palmitoyl-2-
oleoylphosphatidylcholine), POPE (1-palmitoyl-2-oleoylphosphatidylethanolamine), DPPC 
(1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DMPC (1,2-dimyristoyl-sn-glycero-3-
phosphocholine).  
The aim of the study is to understand and explore the mechanistic behaviour of ETB 
receptor in response to two antagonistic ligands: bosentan and K-8794, when embedded in 
POPC, DPPC, POPE and DMPC membrane environments, by means of Molecular Dynamics 
simulations.  
The objectives of the study: 
1. To analyse the scientific literature (previous chapter) about the various cell 
membranes, G-protein coupled receptors, ETB receptor, the ETB receptor targeting 
drugs and Molecular Dynamics simulations. 
2. To analyse the mechanistic basis of bosentan binding to ETB receptor embedded 
in POPC, DPPC, POPE and DMPC membranes. 
3. To analyse the mechanistic basis of K-8794 binding to ETB receptor embedded in 





3. MATERIALS AND METHODS 
3.1. Overview of the structures 
 For the current project two ETB structures were obtained from the Protein Data Bank 
(PDB) (Berman et al., 2000) in the inactive conformation bound to an antagonist bosentan 
(Figure 3.1A) at the resolution of 3.6 Å (ID: 5XPR), and bosentan’s high-affinity ETB 
selective analog K-8794 (Figure 3.1B) at the resolution of 2.2 Å (ID: 5X93) (Shihoya et al., 
2017). Both ligands occupy the traditional orthosteric binding site of the ETB. The residues 
involved in bosentan binding are Asp154, Gln181, Lys182, Lys273, Trp336 and Arg343 as 
reported by Shihoya et al. (2017). While K-8794 showed essentially the same interactions as 
bosentan, the analog interactions with His150 and Ser379 residues were also described. In 
addition, O=S=O of the sulfonamide group of both ligands interacts with the Arg343 that 
induces a slight inward movement of the extracellular region of TM6. Unlike ET-1, both 
bosentan and K-8794 interact poorly with TM7 and thus, do not induce any inward 














Figure 3.1. 2D chemical structures of bosentan (A) and K-8794 (B) (Shihoya et al., 2017). 
 
3.2. Preparation of the structures 
In order to use the selected protein-ligand complexes for modelling and simulation 
purposes with the Maestro v2020.3 by Schrödinger LLC, the structures needed to be free 
from missing atoms, loops and any interatomic clashes. The initial preparation step before the 
usage of Maestro included the removal of the unnecessary protein regions that had been used 
for the crystallization process. Therefore, the T4-lysosyme (mT4L) segment present in the 
third intracellular loop (ICL3) of the receptor was removed from both receptor structures. 
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Apart from the mT4L, the K-8794 bound structure contained one cholesterol molecule, and 
other non-protein atoms such as five sulphate ions, eleven (2R)-2,3-dihydroxypropyl (9Z)-
octadec-9-enoate (monoolein), and 106 water molecules, and the bosentan bound structure 
contained four sulphate ions. 
Figure 3.2 shows the original protein sequences in FASTA format, taken from the 
PDB, with the highlighted residues of mT4L that was removed. Structure visualizations and 
deletion of unwanted residues was carried out using PyMOL Molecular Graphics System 
from Schrödinger LLC (PyMOL | pymol.org, n.d.). 
(A)  
>5XPR_1|Chain A|Endothelin B receptor,Endolysin,Endothelin B 










>5X93_1|Chain A|Endothelin B receptor,Endolysin,Endothelin B 








Figure 3.2. FASTA sequences of PDB ID: 5XPR (A) and 5X93 (B) crystal structures of the ETB 
receptor. The grey highlighted regions are the mT4L segments that were removed during the protein 
preparation 
 Upon removal of the mT4L, the unwanted gaps in the ETB structure at ICL3 were 
modelled using the widely utilized homology modelling tool MODELLER v9.24 (Fiser et al., 
2000; Martí-Renom et al., 2000; Šali & Blundell, 1993; Webb & Sali, 2016) based on user 
defined sequence alignment (Figure 3.3) between the template (X-ray structure sequence) and 
the target (N and C-terminal truncated ETB sequence from the UniProt database (ID: 
P24530)). The alignment was performed using the Clustal Omega tool by European 
Molecular Biology Laboratory – European Bioinformatics Institute (EMBL-EBI) (Clustal 




Figure 3.3. Sequence alignment of the crystal structure sequences (without the mT4L segment) (A) 
PDB ID: 5XPR and (B) 5X93 mT4L free and the ETB UniProt sequence (ID: P24530). The crystal 
structure sequences served as a template, and the UniProt sequence as a target.  
The MODELLER tool works based on a Python script (Figure A1) that generated 20 
separate models. The best model was selected based on Discrete Optimized Protein Energy 
(DOPE) score (Shen & Sali, 2006). DOPE is a statistical potential optimized for model 
assessment, and is part of the MODELLER scoring module. Models with a low DOPE score 
are considered to be of higher quality (Shen & Sali, 2006). The stereo-chemical quality of the 
model was accessed using Maestro Structural Quality Report tool (Bowers et al., 2007) that 
calculates φ (phi) and ψ (psi) angles of each residue in the protein structure, and plots the 
residues on the allowed and disallowed regions on the Ramachandran map.  
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Out of all generated models one representative (one of bosentan-bound and one of K-
8794-bound) model for each complex was selected based on the lowest DOPE score, and the 
least number of residues falling in the disallowed regions of the Ramachandran plot. Overall, 
the created models include only the ETB receptor and bound ligands, and their conformation 
is close to X-ray structure when superimposed with PyMOL by aligning the Cα atoms of the 
receptor backbone. Table A1 shows all the generated models and their DOPE scores. 
Prior to running the Molecular Dynamics (MD) Simulations, the 3D structure was 
prepared using Protein Preparation Wizard (Madhavi Sastry et al., 2013). During the process 
the missing hydrogen atoms were added, incomplete side chains and loops were modelled, 
ambiguous protonation states, and flipped residues were visually investigated and manually 
adjusted if necessary (Madhavi Sastry et al., 2013). 
 
3.3. Molecular Dynamics Simulation Details 
After the structure preparation, the protein-ligand complexes were inserted into the 
four different lipid bilayers (membranes) (Figure 3.4), covering the transmembrane region of 
the protein using the System Builder tool (Bowers et al., 2007).  
 
Figure 3.4. 2D chemical structures of phospholipids. (A) POPC (1-palmitoyl-2-
oleoylphosphatidylcholine), (B) POPE (1-palmitoyl-2-oleoylphosphatidylethanolamine), (C)  DPPC 
(1,2-dipalmitoyl-sn-glycero-3-phosphocholine), (D) DMPC (1,2-dimyristoyl-sn-glycero-3-
phosphocholine) (Shahane et al., 2019). 
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The rest of the parameters were set to default as follows: the protein-ligand complex 
was placed inside the orthorhombic box measuring 10 x 10 x 10 Å in all directions. The 
system was solvated by the TIP3P solvent model, a simple 3-site water model (Jorgensen et 
al., 1983). The force field applied was OPLS3e (Roos et al., 2019) and the unbalanced charge 
in the system was neutralized by adding counter ions. The structures embedded in the 
different membranes produced 16 independent systems (8 apo – ligand-free and 8 holo – 
ligand-bound). Subsequently, all the systems were subjected to the Molecular Dynamics 
Panel by Desmond Molecular Dynamics System developed by D. E. Shaw Research (Bowers 
et al., 2007), included in Maestro v2020.3 to perform the simulations. The simulations were 
carried out in multiple stages using the parameters listed in Table 3.1. 
 
Table 3.1. MD Simulation parameters and protocol. 
Simulation time period (ns) 400 
Recording interval (ps) Trajectory: 50 Energy: 1.2 
Number of frames 10 000 
Ensemble class  NPγT 
Temperature (K) 300 
Pressure (bar) 1.01325 
Surface tensions (bar Å) 0 
System relaxation protocol Default NPγT 
Hardware Puhti supercomputer (Atos BullSequana 
X400 cluster based on Intel CPU) at CSC – 
IT Center for Science (Finland) 
 
Before the actual production run, the system was subjected to a series of step-by-step 
relaxation processes. Firstly, the system was simulated using Brownian Dynamics (BD) in 
NVT ensemble at 10 K temperature for 100 ps by restraining solute heavy atoms. This was 
followed by BD simulation in NPT ensemble at 100 K for 20 ps, with solute non-hydrogen 
atoms restrained. Afterwards, an MD simulation of 10 ps in NPγT ensemble was carried out, 
using a Nose–Hoover chain thermostat (Martyna et al., 1992) and Martyna–Tobias–Klein 
barostat (Martyna et al., 1994) set to 100 K and 1.01325 bar pressure, while restraining non-
hydrogen solute atoms. Next, an MD simulation was run for 10 ps in NPγT ensemble, heating 
from 100 to 300 K by using Nose–Hoover chain thermostat and Martyna–Tobias–Klein 
barostat. Subsequently, while gradually releasing the restrains the system was subjected to an 
MD simulation in NVT ensemble for 24 ps, maintaining the temperature at 300 K with the 
Nose–Hoover thermostat and the pressure at 1.01325 bar with the Martyna–Tobias–Klein 
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barostat. Finally, the unrestrained system was simulated again in NVT ensemble (Bowers et 
al., 2007). 
For the production simulation, the NPγT ensemble class was chosen, to maintain the 
surface tension of the system, and to ensure that the simulation box does not deform 
significantly in the plane of the membrane while the pressure is applied normal to the 
membrane surface (Bowers et al., 2007, Molecular Dynamics Panel, n.d.). All the MD 
simulations were carried out using the Finnish IT Center for Science (CSC) high performance 
computing facility. 
 
3.4. Preliminary Trajectory Analysis 
Several preliminary trajectory analyses were performed to acquire details of the 
structural stability of the complexes. The trajectory analysis for each system was carried out 
using the Simulation Interactions Analysis tool (Bowers et al., 2007), from which the Root 
Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF) and Radius of 
Gyration (Rg) values were estimated, which is a fully automated process. In addition, the 
total number of hydrogen bonds was calculated through the Interaction Count tool. All the 
analyses mentioned were performed on the entire length of the MD trajectories.  
RMSD measures the average change in displacement of Cα atoms, for a particular 
frame compared to the reference structure (the first frame of the simulation) over a set of 
atoms. The RMSD is calculated based on the following equation for the entire trajectory 
(Bowers et al., 2007): 






𝑖=1      (1) 
where, x is the frame to calculate the RMSD for; N is the number of atoms in the atom 
selection; tref is the reference time (frame); rꞌ is the position of the selected atoms in the x 
frame after superimposing on the reference frame.  
 RMSF measures the structural flexibility of Cα atoms along a protein chain. The N-
terminus and C-terminus ends, and loops of the protein show higher fluctuations, while rigid 
parts of the protein (helices and sheets) fluctuate less. RMSF is calculated by the following 
equation (Bowers et al., 2007): 




′(𝑡)) − 𝑟𝑖(𝑡𝑟𝑒𝑓))2 >
𝑇
𝑡=1    (2) 
where T is the trajectory time over which the RMSF is calculated; tref is the reference time 
(frame); ri is the position of the residue i; rꞌ is the position of atoms in residue i after 
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superimposition on the reference frame; angle brackets < and > indicate that the average of 
the square distance is taken over the selection of atoms in the residue.   
 Radius of Gyration (Rg) measures the compactness of a structure and the evolution of 
it throughout the simulation. It is calculated by using the following equation (Bowers et al., 
2007): 
     Rg = √
1
𝑁
∑ (𝑟(𝑖) − 𝑟𝑐𝑒𝑛𝑡𝑒𝑟)2
𝑁
𝑖=1     (3) 
where N is the number of protein atoms; ri and rcenter are the position of atom i with respect to 
the centre of mass of the molecule. 
 Hydrogen Bond Count measures the number of hydrogen bonds that are present 
between the protein and its binding partner over time. Hydrogen bonds contribute to the 
stability of the complex (longer ligand residence times) and binding site rigidity (Torrens-
Fontanals et al., 2020). Parallel to the Hydrogen Bond Count measurements, hydrogen bonds 
of the last trajectory frame (at 400 ns) for every ligand-bound system were visually 
investigated. 
  
3.5. Principal Component Analysis 
An essential dynamics analysis based on the Principal Component Analysis (PCA) 
was carried on all the MD trajectories by running the trj_essential_dynamics.py (Amadei et 
al., 1993) program on all the MD trajectories available in Maestro v2020.3 by Schrödinger 
LLC. The analysis performed on all the snapshots obtained from the last 200 ns (from 200 ns 
to 400 ns) for 16 trajectories (both ligand-bound complexes and apo structures). The PCA 
analysis produced 10 principal components (PCs modes) for every trajectory.  
In PCA, a covariance matrix (Cij) is built, using the coordinates of Cα atoms. Then the 
eigenvalue decomposition of the Cij matrix is used to obtain eigenvectors (principal 
components) of the MD trajectories. The following equation is used to create the Cij matrix 
(Amusengeri et al., 2020; Chen et al., 2016): 
                         𝐶𝑖𝑗 = (𝑋𝑖 − 𝑋?̅?)(𝑋𝑗 − 𝑋?̅?) > (𝑖, 𝑗 = 1,2, … . , 3𝑁)    (4) 
where Xi is the Cartesian coordinate of the ith Cα atom, N is the Cα atom used in building the 
matrix. 
The eigenvectors are obtained by calculating the diagonal matrix Q using the 
following equation (Amusengeri et al., 2020; Chen et al., 2016): 
                                                               𝑄 =  𝑇𝑇𝐶𝑖𝑗𝑇      (5) 
34 
 
where T is the orthogonal coordinate transformation matrix, and Cij is the covariance matrix. 
Additionally, the first principal component (PC1) was presented as a porcupine plot 
by visualising the secondary structure and loops of the protein using PyMOL, to analyse 
structural changes and direction of motion captured by the PC of the ETB receptor. In the 
porcupine plot, the black arrows represent the direction of motion of every Cα atom, while 
the length represents the strength of the movement (Chen et al., 2016). 
 
3.6. Free Energy Landscape 
The first and the second principal component (PC1 and PC2) were plotted as Free 
Energy Landscapes (FEL). FEL assists the visualization and effortless study of the structural 
clusters (conformers) formed throughout the simulation and/or for the purpose of 
understanding the structural stability of a protein. This method also facilitates the discovery 
of the accessible conformational space of a protein to demonstrate the flexibility of the 
complex systems (Amusengeri et al., 2020; Chen et al., 2016). For the purpose of the project, 
the first two PCs were chosen because they contain the largest percentage of variance of the 
MD simulations. The FEL was calculated using the following equation (Amusengeri et al., 
2020; Chen et al., 2016): 
                                         ∆𝐺𝑖 = −𝑘𝐵𝑇[𝑙𝑛𝑃(𝑖) − 𝑙𝑛𝑃𝑚𝑎𝑥]       (6) 
where kB is the Boltzmann constant, T is the temperature set to 300 K, i are principal 
components, P is the probability distribution of the molecular systems along some coordinate 
i, Pmax ensures that the lowest free energy minima is set to 0. 
 
3.7. Binding free energy calculations by MM/GBSA 
For the binding free energy (BFE) calculations the Molecular Mechanics with 
Generalized Born Surface Area (MM/GBSA) method was utilized (Bowers et al., 2007). The 
method’s purpose is to predict the strength of interactions between a protein and its ligand by 
calculating BFE. A total of 100 evenly spaced snapshots from the last 200 ns of trajectories 
of the ligand-bound simulations were considered. 
The total binding free energy of a receptor-ligand complex, and the contribution of 
different interaction components to the total energy was also calculated. The latter was done 
to evaluate the variables that affect the total energy, and their contribution to the total binding 
free energy. Additionally, per-residue decomposition energies for all protein residues were 
calculated. It was done to detect the hotspot residues that have the highest contribution 
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(binding strength) to the total binding free energy of the ligand binding to the receptor. In 
addition, the residues with a BFE of -2 kcal/mol and lower were visualised as a 3D image 
taken from the snapshot structure at 300 ns of the simulation. However, the residues 
identified and visualised must be the same throughout all of the simulations. 
The MM/GBSA method was applied by running the thermal_mmgbsa.py script 
available in the Schrödinger’s Maestro suite, where it incorporates the Prime module (Bowers 
et al., 2007). This method estimates the free energy of binding of a receptor-ligand complex, 
separate ligand or just receptor structures (Ylilauri & Pentikäinen, 2013). As described by 
Peddi et al. (2018), Prime/MMGBSA is binding free energy (ΔGbind), and can be viewed as 
an equation at Eq. 8 in more detail: 
A combination of OPLS molecular mechanics energies (EMM), a VSGB solvation 
model for polar solvation (GSGB), and a nonpolar solvation term (GNP) composed of 
the non-polar solvent-accessible surface area (SASA) and van der Waals interactions 
(p. 9).  
The equation for calculating the binding free energy (ΔGbind) is as follows ( 
Schrödinger LLC, 2021; What do all the Prime MM-GBSA energy properties mean? | 
Schrödinger, n.d.): 
                             ∆Gbind = 𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − (𝐺𝑙𝑖𝑔𝑎𝑛𝑑 (𝑚𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑) + 𝐺𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 (𝑚𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑))  (7) 
where G is the energy of a complex, ligand and receptor.  
Eq. 7 can be rewritten based on Lyne et al. (2006) as: 
                                                ∆Gbind = ∆𝐸𝑀𝑀 + ∆𝐺𝑠𝑜𝑙𝑣 + ∆𝐺𝑆𝐴                             (8) 
where ΔEMM is dissimilarity in energies between the complex structure and the sum of the 
energies of the ligand and the apo structure (7) or sum of electrostatic (Eele), lipophilic (Elipo) 
and van der Waals (EVdW) energies; ΔGsolv (solvation free energy) is the difference in the 
GBSA solvation energy of the receptor-ligand complex and the sum of the solvation energies 
for the ligand and apo receptor; ΔGSA is the difference in the surface area energy for the 
receptor-ligand complex and the sum of the surface area energies for the ligand and apo 
receptor.  
 Additionally, the total energy with the contributions of the different components is 
calculated with the equation Eq. 9 presented below, as reported by Li et al. (2011): 
∆Gtotal(bind) = 𝐸𝑐𝑜𝑢𝑙𝑜𝑚𝑏 + 𝐸𝑐𝑜𝑣𝑎𝑙𝑒𝑛𝑡 + 𝐸𝐻𝑏𝑜𝑛𝑑 + 𝐸𝑙𝑖𝑝𝑜 + 𝐸𝑝𝑎𝑐𝑘𝑖𝑛𝑔 + 𝐸𝐺𝐵 + 𝐸𝑉𝑑𝑊   (9) 
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that generally includes Coulomb energy, covalent binding energy, hydrogen-bonding 
correction, lipophilic energy, π-π packing correction, generalized Born (GB) electrostatic 
solvation energy, and van der Waals energy, respectively (Li et al., 2011). 
 
3.8. Dihedral Angle Analysis 
 Dihedral angle analysis can be used to identify the conformational change that 
occurred in a specific residue due to ligand binding over a time period (Chen et al., 2016). A 
dihedral angle can be described as the angle between two adjacent planes in the polypeptide 
backbone. The dihedral angle consists of φ (phi) and ψ (psi) angles. The φ angle involves the 
backbone atoms of C-N-Cα-C, while the ψ angle involves the N-Cα-C-N atoms (Echave, 
2009).  
 The dihedral angle analysis was performed on the residues that have the highest 
contribution to the total BFE (hotspot residues). For that purpose, Add Workspace 
Measurement tool present in Maestro was utilized to measure the dihedral angle considering 
both apo and holo conformations, using the last 200 ns (200 ns – 400 ns range) of the 
trajectories. To visualise the change in dihedral angle, FELs were constructed by plotting the 
φ and ψ angles. 
 
3.9. Figure plotting and graphical visualisation 
 Overall, the protein structure analysis and visual investigation was performed using 
PyMOL and Maestro v2020.3 by Schrödinger LLC graphical user interface (GUI). 
 All the graphs were plotted using Python libraries developed for data analysis, such as 




4. RESULTS AND DISCUSSION 
Firstly, the MODELLER software created 20 structures per ligand, as seen in Table 
A1, and automatically calculated its model assessment scores based on DOPE method (Fiser 
et al., 2000; Martí-Renom et al., 2000; Šali & Blundell, 1993; Webb & Sali, 2016). The 
chosen bosentan-bound ETB receptor model had a DOPE score of -40353.57031 and its 
residues were 97.6 % in the most favoured regions in the Ramachandran plot. For the K-
8794-bound ETB model, the chosen model had a DOPE score of -42179.47266 and residues 
were 98.6 % in the most favoured regions. 
After the initial system preparations (apo and holo complexes), the systems were 
subjected to MD simulation, embedded in four different membranes (POPC, DPPC, POPE, 
DMPC). A total of 16 molecular dynamics simulation trajectories were obtained:  
 4 for bosentan-bound ETB; 
 4 for bosentan-free ETB (APO);  
 4 for K-8794-bound ETB;  
 4 for K-8794-free ETB (APO).  
Each system was analysed to understand the structural stability, mechanistic 
behaviour, and contributions to the binding free energy due to ligand binding to ETB receptor. 
The outputs from the final MD simulations (protein + membrane) will be referred to as 
LIGAND-RECEPTOR-MEMBRANE system, and for APO as LIGAND-free-RECEPTOR-
MEMBRANE system. 
 
4.1. Structural stability analysis 
4.1.1. Root Mean Square Deviation (RMSD) analysis 
 RMSDs for all of the eight ligand-bound ETB complexes and eight ligand-free ETB 
(APO) structures were calculated. RMSD plots revealed structural deviations of Cα atoms in 
the four different types of membranes, for the previously mentioned complexes and 
structures.  
As seen in Figure 4.1, all 16 systems exhibited fluctuations between 2 to 3 Å. Most 
APO systems displayed high fluctuations, especially the K-8794-free-ETB-DPPC system. 
Some displayed stability throughout all of the MD simulations (POPE and DMPC). The 
deviations for APO were expected, because of an empty orthosteric binding pocket, since 
there is no ligand to induce or inhibit the receptor activity.  
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Bosentan-ETB-POPC system showed medium fluctuation: it first reached equilibrium 
after 100 ns, and then later after 200 ns. While the K-8794-ETB complex embedded in POPC 
showed a very high deviation for the first 150 ns and started to maintain stability at around 
160 ns. The Bosentan-ETB in the DPPC system maintained stability throughout all of the MD 
simulation time. Similar behaviour was observed in the K-8794-ETB-DPPC system, as it also 
maintained stable equilibrium during the simulation. Next, a relatively high instability is seen 
in the Bosentan-ETB-POPE system for the first 200 ns, but during the rest of the simulation 
time, the system has attained equilibrium by staying at around the 3.5 Å range. K-8794-ETB-
POPE system at the start of the simulation exhibited a slight deviation of about 80 ns and 
maintained stability for the rest of the MD simulation. Both Bosentan-ETB-DMPC and K-
8794-ETB-DMPC retained a stable plateau for all 400 ns.  
These findings suggest that the trajectory of the last 200 ns (range of 200 ns – 400 ns) 
is reliable and can be used for further analysis, such as free binding energy estimation, 




Figure 4.1. Root mean square deviation (RMSD) estimated for the Cα atoms throughout 400 ns for 
the bosetan (red) and K-8794-bound (blue) to the ETB receptor, and ligand-free (yellow) states 
embedded into the POPC, DPPC, POPE, and DMPC membranes. Solid lines represent an average of 
every 50 frames (50 frames per 1 ns). 
 
4.1.2. Root Mean Square Fluctuation (RMSF) analysis 
RMSF for all of the eight ligand-bound ETB complexes and eight ligand-free ETB 
(APO) structures were calculated. RMSF has revealed structural flexibility of Cα atoms in the 
four different types of membranes, for the previously mentioned complexes and structures.  
All 16 systems exhibited fluctuations as shown in the RMSF Figure 4.2. After a 
further 3D structure and RMSF analysis, it was revealed that the six peaks represent the most 
40 
 
fluctuating areas of the protein. These areas were the three extracellular and three 
intracellular loops, while the helices and sheets were more rigid and did not show high 
fluctuations. Additionally, the sudden slopes at the beginning and the end of the RMSF plots 
represent the N-terminus and the C-terminus of the receptor that were expected to fluctuate. 
Loops are more flexible because they are the region of the protein that is free from structural 
integrity. Comparing all of the ligand-bound ETB systems with their APO equivalent, it is 
clearly seen that the APO structure deviated the most. This actively demonstrates that protein 
without inhibitor bound is more flexible, compared to the effector bound. However, when an 
effector binds to the binding pocket of the protein, this instigates the movement of 
intracellular (IC) loops trapping the effector in a cage-like conformation (Kempner, 1993). 
 Interestingly enough, in most of the systems (Figure 4.2), except in the K-8794-ETB-
POPE and K-8794-ETB-DMPC systems, the highest fluctuations reaching 6 Å was of ICL3 
(Lys303 – Asn312) that connects TM5 to TM6. In all systems, the least fluctuations starting 
at 1.5 Å were of intracellular loop 1 (ICL1) (Asn129 – Leu139) that connects TM1 to TM2. 
Except in the Bosentan-ETB-POPC system, ECL1 (Leu162 – Ala171) had the least deviations 





Figure 4.2. Root mean square fluctuations (RMSF) estimated for the Cα atoms throughout 400 ns for 
the bosetan (red) and K-8794-bound (blue) to the ETB receptor, and ligand-free (yellow) states 
embedded into the POPC, DPPC, POPE, and DMPC membranes. Solid lines represent an average of 





4.1.3. Radius of Gyration (Rg) analysis 
The Radius of Gyration (Rg) for all the 16 complexes was calculated, to analyse the 
compactness and stability of the protein along the simulation time. More compact structures 
display smaller values (Ivankov et al., 2009).  
All 16 systems experienced significant differences in the fluctuations as seen in 
Figure 4.3. Bosentan-ETB-POPC exhibited fluctuations between 22.40-23.00 Å, and its APO 
showed similar compactness. On the other hand, K-8794-ETB-POPC showed high 
fluctuations at the start of the MDS but later seemed to maintain compactness starting from 
~150 ns between ~22.00-22.25 Å. Comparing the two systems mentioned previously, the K-
8794-bound receptor maintained higher compactness. While its APO equivalent maintained a 
lower degree of compactness throughout most of the simulation. The Bosentan-ETB-DPPC 
system maintained compactness between ~22.00-23.00 Å, similarly to its APO structure. K-
8794-ETB-DPPC exhibited compactness between 50 to 230 ns at ~22.25-22.50 Å and then 
later showed plateau from 230 to 400 ns at around 22.20 Å, which meant that the structure 
over the simulation time stayed relatively compact. However, between the two DPPC 
systems, K-8794-bound protein was more compact than bosentan-bound. Both bosentan-
bound and K-8794 bound structures embedded in the POPE system showed similar levels of 
compactness to their APO equivalent. Comparing the Bosentan-ETB-POPE system with the 
K-8794-ETB-POPE, the former experienced a higher degree of compactness ranging at 
~22.40 Å. While the latter was at ~22.50 Å. The Bosentan-ETB-DMPC and K-8794-ETB-
DMPC systems expressed similar compactness levels, with bosentan-bound showing higher 
fluctuations at the beginning of the simulation. However, the following exhibited better 
compactness at around 22.30 Å from 230 to 240 ns, compared to K-8794-bound ETB with 
lower compactness at around 22.40 Å throughout the MDS.  
Most of the APO structures in all of the MD simulations showed similar deviations to 
their ligand-bound equivalent structures. Except for APO structure in POPC membrane as 
seen in Figure 4.3 experienced higher fluctuations later in the simulation, than the ligand-
bound structure: APO form showed less compactness than ligand-bound form.    
Out of all the 16 systems, the most compact were the K-8794-ETB-POPC and K-
8794-ETB-DPPC systems. The least compact systems were Bosentan-ETB-POPC and K-




Figure 4.3. Radius of Gyration (Rg) plots of the protein structure compactness throughout 400 ns for 
bosetan-bound (red) and K-8794-bound (blue) ETB receptor, and ligand-free (yellow) states embedded 
into the POPC, DPPC, POPE, and DMPC membranes. Solid lines represent an average of every 50 





4.1.4. Hydrogen Bond Count analysis 
 Ligands usually bind to the protein by non-covalent bonds such as hydrogen bonds. 
Hydrogen bonds (H-bonds) are important for ligand binding specificity, metabolization and 
adsorption. These bonds also contribute to the binding site rigidity, and stability of the 
complex (longer ligand residence times) (Torrens-Fontanals et al., 2020). Therefore, H-bond 
Count between binding residues and ligand was calculated for all of the 8 MD simulations. 
Additionally, the H-bonds between ligand and protein orthosteric binding pocket residues 
(Asp154, Ly161, Gln181, Lys182, Lys273, Arg343, Trp336, Ile372) at 4 Å distance of the 
last trajectory frame (400 ns) for every ligand-bound system were visualised. 
  The evolution of the number of hydrogen bonds in time is visualised in Figure 4.4. 
All the 8 MD simulation systems exhibit clear fluctuations in the number of H-bonds. 
Bosentan-ETB-POPC systems experienced as high as 7 hydrogen bonds. However, it later 
exhibited a low in the number of H-bons between 100-150 ns averaging at ~2. Starting from 
~150 ns the system reached a plateau averaging at around 4 hydrogen bonds, with the last 
frame having ~3 stable bonds. K-8794-ETB-POPC experienced a very high number of H-
bonds: rising at around 6 bonds (90-150 ns), then dropping to ~5 bonds lasting for 150 ns, 
and then dropping again to 2 but starting to rise at ~310 ns, with the final frame stabilizing at 
4 bonds (Figure 4.4). Bosentan-ETB and K-8794-ETB structures embedded in DPPC 
membrane, displayed relatively stable bonds averaging at 4 for bosentan-bound ETB, and 
after 50 ns for K-8794 system maintaining 2 bonds. The last frame had 4 stable bonds for 
bosentan-bound and 3 stable hydrogen bonds for K-8794-bound. The Bosentan-ETB-POPE 
system also displayed low hydrogen bond deviations with an average of 3 hydrogen bonds. 
However, the K-8794-ETB-POPE system experienced high fluctuations for ~150 ns, but 
reached equilibrium at ~160 ns and remained stable displaying 4 hydrogen bonds. The 
bosentan-ETB in the DPPC membrane experienced uneven fluctuations with a sudden drop to 
~1 hydrogen bond at 180-230 ns interval, then suddenly rising with visible fluctuations and 
stabilizing at 340 ns with 3 hydrogen bonds. However, K-8794-ETB-DMPC exhibited high 
fluctuations for ~200 ns reaching 8 bonds but eventually stabilized during the last 200 ns 
having 3 hydrogen bonds.  
 Throughout all the systems, the hydrogen bond count change analysis revealed that 
the average stable hydrogen bond count was 3. Additionally, all the systems reached their 
equilibrium starting from 200 ns that indicates the 200-400 ns interval is a reliable range for 




Figure 4.4. Hydrogen Bond plots indicating the change in number of Hbonds between protein and 
ligand throughout 400 ns for bosetan-bound (red) and K-8794-bound (blue) ETB receptor embedded 
into the POPC, DPPC, POPE, and DMPC membranes. Solid lines represent an average of every 50 




 Further analysis of the receptor-binding site at 4 Å distance from both ligands 
revealed the residues that contributed to the stable hydrogen bonds between ligand and ETB 
receptor (Figure 4.5). For this, the last frame from the MD trajectory was extracted and used. 
ETB in complex with bosentan in POPC membrane (Figure 4.5 A) formed H-bonds 
between Gln181, Lys273, and Arg343. Similarly, hydrogen bonds are stabilized in ETB in 
complex with K-8794 in POPC (Figure 4.5 B), however, instead of maintaining a bond with 
Gln181, a new hydrogen bond was established between K-8794 and Lys182, and an 
additional H-bond with Ile372. In the DPPC system bosentan maintained hydrogen bonds 
with Asp154, Lys182, Lys273 and, Arg343, while K-8794 with Lys161, Lys273 and Arg343 
(Figure 4.5 C & D). ETB in complex with bosentan in POPE membrane shows the hydrogens 
bonds formed by Lys273, Arg343, and Ile372 are stably maintained (Figure 4.5 E). While as 
shown in Figure 4.5 F, K-8794 formed hydrogen bonds with Lys182, Lys273, and Arg343 
formed two bonds between one nitrogen atom and one oxygen atom. Both bosentan and K-
8794 in the DMPC membrane system formed hydrogen bonds with the same ETB binding 
pocket residues. The bosentan – with Lys182, Lys273, and Arg343 between the oxygen 
atoms of O=S=O group as shown in the Figure 4.5 G. K-8794 formed H-bonds between 
oxygen atoms of O=S=O group with Lys273 and Arg343, while Lys182 formed a hydrogen 
bond with the oxygen, which connects benzene ring to pyrimidine (Figure 4.5 H). 
Ultimately, in all of the eight ligand-receptor-membrane systems, both ligands 
exhibited H-bonds forming between O=S=O i.e. the sulfonamide group of the ligand and 
protein residues Lys273 and Arg343. The residues Lys182, Lys273, Arg343 for both 
bosentan and K-8794 are in accordance with the fact that they form relevant H-bonds and 
contribute to the ligand binding as stated by Shihoya et al. (2017). More established H-bonds 
between ligand and surrounding residues may indicate stronger binding results. However, 
some hydrogen bonds can minimize the binding affinity of a ligand because of the 
unfavourable desolvation effect (Klebe, 2013). Therefore, further analysis such as free 
binding energy (FBE) estimations is necessary. Additionally, when several ligands are 
compared between each other, and they differ by a functional group that forms the H-bonds 






Figure 4.5. ETB receptor orthosteric binding site showing stable hydrogen bonds at 4 Å distance 
between ligand and binding site residues that formed during the last MDS trajectory frame (400 ns) of 
all ligand-bound ETB and membrane systems. The black dashed lines represent hydrogen bonds and 
sticks represent relevant residues. Bosentan – red sticks, K-8794 – blue sticks. (A) Bosentan-ETB-
POPC, (B) K-8794-ETB-POPC, (C) Bosentan-ETB-DPPC, (D) K-8794-ETB-DPPC, (E) Bosentan-
ETB-POPE, (F) K-8794-ETB-DPPC, (G) Bosentan-ETB-DMPC, (H) K-8794-ETB-DMPC. 
48 
 
4.2. Binding Free Energy estimation 
 By extracting 100 evenly spaced snapshots from the last 200 ns of the trajectory of the 
ligand-bound MD simulations, the overall binding free energy (BFE or ΔGbind) of the 
complexes was estimated by MM/GBSA approach. The MM/GBSA predicts the binding 
strength between protein and its binding partner. In the current study, the residues that 
contribute to the ligand-binding through maximum BFEs (lowest minima) called hotspots 
have been identified. Lower BFE contributing residues are also favourable to the ligands 
binding. 
In addition, the contribution to the total binding free energy from different components 
such as Coulomb energy, covalent binding energy, hydrogen bonding correction, π-π packing 
correction, generalized Born electrostatic solvation energy, and van der Waals energy was 
calculated for the 200 ns – 400 ns range trajectory of all ligand-bound system. The BFE 
estimation includes corrections of H-bonds and π-π packing. As stated by Li et al. (2011) 
these two values must be correct for an accurate protein structure prediction and stabilization 
of hydrophobic cores. 
Performed analysis results (Table 4.1) revealed that for ETB receptor in complex with 
bosentan the most favourable membrane was DPPC with BFE being -85.8762 kcal/mol, then 
followed by DMPC with BFE being -77.1620 kcal/mol, POPE with BFE being -73.7519 
kcal/mol. The least favourable was POPC with BFE being -66.2156 kcal/mol. On the 
contrary, for ETB receptor in complex with K-8794 the lowest minimum of -83.1504 
kcal/mol was revealed to be when the receptor was embedded in the POPE membrane. Then 
favourability decreased following DMPC with BFE being -81.3768 kcal/mol and DPPC with 
-72.0154 kcal/mol. But similarly, as with bosentan, the least unfavourable membrane 
revealed to be POPC with a BFE value of -65.7402 kcal/mol.  
The result revealed (Table 4.1) that for bosentan and K-8794 bound ETB receptor in 
POPC, DPPC, POPE and DMPC membrane environment, the primary contributors in the 
BFE were Coulomb energy (ΔGcoulomb) and van der Waals energy (ΔGVdW). The least 
favourable contributions were covalent binding energy (ΔGcovalent) and generalized Born 
electrostatic solvation energy (ΔGGB). The decrease of van der Waals energy is one of the 
characteristics that display weaker ligand binding (Chen et al., 2015). Even though the 
difference of van der Waals energies, when compared between membrane environments, is 
minor as presented in Table 3.1, it can still demonstrate ligand binding affinity and membrane 
environment favourability. Since ΔGVdW is one of the biggest contributors to BFE. Therefore, 
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the lower the BFE is the stronger ligand binding and the more favourable membrane 
environment.  
 
Table 4.1. Binding free energies (kcal/mol) and their separate components, calculated by MM/GBSA 













































POPC -48.9200 0.9443 -3.8652 -20.9129 -2.4458 60.7323 -51.7483 -66.2156 
DPPC -62.5312 2.3788 -3.8716 -27.0005 -4.1324 72.7557 -63.4750 -85.8762 
POPE -49.0362 3.0078 -3.4807 -26.3352 -3.8371 66.0648 -60.1353 -73.7519 
DMPC -42.9940 1.4615 -3.0339 -25.9265 -5.0364 58.1871 -59.8199 -77.1620 
Membrane K-8794 
POPC -59.6918 3.1022 -3.7031 -20.2427 -3.9714 82.2483 -63.4817 -65.7402 
DPPC -58.4486 -0.2837 -1.9224 -25.4346 -3.6920 82.7090 -64.9431 -72.0154 
POPE -54.0754 4.3460 -3.2990 -29.8374 -4.1714 76.4793 -72.5925 -83.1504 
DMPC -54.4193 2.5841 -3.0706 -28.3599 -3.8806 76.0698 -70.3001 -81.3768 
 
By analysing the per-residue decomposition (PRD) energies, two residues that 
contribute the most (hotspots) to the binding of both bosentan and K-8794 were identified 
(Figure 4.6). As shown in Figure 4.6 the hotspot residues, represented as the most negative 
energies, were Lys182 and Trp336. In accordance with Shihoya et al. (2017), these residues 
are important for ligand binding to the ETB receptor. The other residues also exhibited 




Figure 4.6. Per-residue BFEs (kcal/mol) estimated for bosentan and K-8794 in complex with ETB 
receptor embedded in POPC (blue), DPPC (yellow), POPE (green) and DMPC (red) membranes. BFE 
was extracted from 100 evenly spaced snapshots from the last 200 ns trajectory of the ligand-bound 
ETB receptor MD simulations. 
The overall ETB receptor residues that are of BFE -2 kcal/mol and lower, and appear 
in all of the systems, were identified and visualised in a 3D image for which the coordinates 
were extracted at 300 ns frame (Figure 4.7). For both bosentan and K-8794, as mentioned 
before, hotspot residues were Lys182 and Trp336.  
For ETB in complex with bosentan, Lys182 had far greater values than Trp336. In the 
Bosentan-ETB-POPC system Lys182 BFE was -5.928 kcal/mol, and Trp336 – -3.428 
kcal/mol (Figure 4.7 A). For the Bosentan-ETB-DPPC system, Lys182 reached -6.5512 
kcal/mol, while Trp336 was -2.428 kcal/mol (Figure 4.7 C). Lys182 exhibited a BFE value of 
-5.6572 kcal/mol, and Trp336 of -3.2918 kcal/mol in the Bosentan-ETB-POPE system (Figure 
4.7 E). Lastly, for the Bosentan-ETB-DMPC system, Lys182 was -6.0874 kcal/mol, and 
Trp336 was -4.0919 kcal/mol (Figure 4.7 G).  
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For ETB in complex with K-8794, similarly to bosentan Lys182 displayed more 
favourable BFE values than Trp336. In K-8794-ETB-POPC system Lys182 exhibited -6.2063 
kcal/mol BFE, while Trp336 – -4.4004 kcal/mol (Figure 4.7 B). For the K-8794-ETB-DPPC 
system, Lys182 displayed a BFE value of -3.9672 kcal/mol, and Trp336 displayed -2.3608 
kcal/mol (Figure 4.7 D). The Lys182 exhibited BFE at -6.3099 kcal/mol, while Trp336 
exhibited -4.7622 kcal/mol in the K-8794-ETB-POPE system (Figure 4.7 F). Finally, in the 
K-8794-ETB-DMPC system, both hotspot residues exhibited similar BFE values, Lys182 
BFE value was at -5.8749 kcal/mol, and Trp336 at -5.9025 kcal/mol (Figure 4.7 H).  
On the whole, when comparing the two hotspot residue interactions with bosentan and 
K-8794 (Figure 4.6 – 4.7), the K-8794 had more favourable interactions with both Lys182 
and Trp336 over bosentan. Since K-8794 is of higher affinity than bosentan, these findings 
are in accordance with the experimental results provided by Shihoya et al. (2017), where for 








Figure 4.7. ETB receptor (cartoon) orthosteric binding site displayed using the coordinates extracted 
from the 300 ns time frame. Bosentan is presented as red sticks, and K-8794 as blue sticks. Hotspot 
residues are highlighted as the enlarged spheres in orange having BFE of the lowest minima, and 
yellow having BFE above -4 kcal/mol. All of the other small spheres are residues of BFE higher 
minima than that of hotspot residues (lowest minima). (A) Bosentan-ETB-POPC, (B) K-8794-ETB-
POPC, (C) Bosentan-ETB-DPPC, (D) K-8794-ETB-DPPC, (E) Bosentan-ETB-POPE, (F) K-8794-ETB-
DPPC, (G) Bosentan-ETB-DMPC, (H) K-8794-ETB-DMPC. 
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4.3. Principal Component Analysis (PCA) 
 With the help of Principal Component Analysis (PCA) and Free Energy Landscape 
(FEL), it is possible to identify protein clusters (conformers) that formed during simulation 
time and study the protein flexibility by the wideness of the accessible conformational space 
visited. The PCA is often called Essential Dynamics (ED). It is an advanced MDS trajectory 
analysis method used for understanding and identifying the atomic fluctuations 
(conformational changes) of proteins. The changes are usually related to the function or 
biological properties. PCA works by reducing the dimensionality of the conformational space 
for the purpose of extracting the large scale collective motions of atoms. The large variance 
or total motion, which is coordinated to each other, of atoms is stored in the first principal 
component (PC1) and the rest of the variance is continued to be stored in the following 
principal components (PCs). Thus, having the largest variance, the first two principal 
components define the essential subspace of the system (Amusengeri et al., 2020; Chen et al., 
2016).  
FEL was built by plotting the first two PCs of PCA from the MD simulation data of 
ligand-bound complexes and APO structure. PC1 and PC2 were utilized, because of their 
high variance of MD simulation data. Low-lying energy basins (purple) represent visited 
clusters (conformers), and broad areas of FEL represent accessible conformational space 
(transition subspace). The targeted trajectory range for the analysis is 200 ns – 400 ns, as 
agreed by RMSD analysis results. 
 As seen in Figure 4.8, when comparing the Bosentan-free-ETB-POPC (APO 
Bosentan) system with the Bosentan-ETB-POPC (Bosentan) system, the APO structure 
formed one conformer, as presented by a single well energy landscape. While the Bosentan 
system formed two clusters (two low energy basins). However, both the complex and the 
structure spanned broad conformational spaces, with the APO structure exhibiting more 
flexibility. Similar events are seen when comparing K-8794-free-ETB-POPC (APO K-8794) 
and K-8794-ETB-POPC (K-8794) systems: APO structure demonstrated one cluster formed, 
while K-8794 complex formed two. The APO system displayed higher flexibility, because of 
broader conformational space, unlike the K-8794 system. 
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Figure 4.8. Free energy landscape (FEL) plots of bosentan and K-8794 bound and APO ETB receptor 
embedded in POPC membrane, built by two principal components (PC1 and PC2) of MD trajectory. 
The landscapes are color-coded from yellow (energy maxima) to purple (energy minima). 
When comparing bosentan-bound ETB (Bosentan) structure and its equivalent APO 
(APO Bosentan) structure embedded in DMPC membrane (Figure 4.9), the APO structure 
obtained three conformations, while bosentan-bound formed two. The ligand-free structure 
also spanned a wider conformational space, unlike ligand-bound. K-8794-bound and unbound 
systems experienced different events. Ligand-free structure (APO K-8794) obtained one 
cluster, similarly to ligand-bound (K-8794). However, the APO structure also spanned wider 
conformational space. Therefore, the exhibited conformational space broadness of the 
unbound ETB receptor indicates a highly flexible system, before transitioning to the clusters.  
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Figure 4.9. Free energy landscape (FEL) plots of bosentan and K-8794 bound and APO ETB receptor 
embedded in DPPC membrane, built by two principal components (PC1 and PC2) of MD trajectory. 
The landscapes are color-coded from yellow (energy maxima) to purple (energy minima). 
Systems of ligand-bound and ligand-free ETB receptor embedded in the POPE 
membrane exhibited different conformational events (Figure 4.10). Comparing bosentan in 
complex with ETB receptor (Bosentan) with its ligand-free structure (APO Bosentan), the 
APO system visited two metastable conformers, while ligand-bound visited one. However, 
the bosentan-bound system displayed a broader conformational space, unlike the bosentan-
unbound. The K-8794-free (APO K-8794) and bound structure (K-8794) FEL revealed only 
one formed conformer for both systems. In addition, both systems explored wide 
conformational space, indicating high flexibility, before obtaining the clusters formed.  
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Figure 4.10. Free energy landscape (FEL) plots of bosentan and K-8794 bound and APO ETB 
receptor embedded in POPE membrane, built by two principal components (PC1 and PC2) of MD 
trajectory. The landscapes are color-coded from yellow (energy maxima) to purple (energy minima). 
 As seen in Figure 4.11, bosentan-unbound (APO Bosentan) ETB receptor structure 
formed one cluster, but spanned a wide conformational space, before transitioning to that 
cluster when embedded in the DMPC membrane. However, bosentan-bound (Bosentan) 
obtained two conformers, and displaying the structure has visited transitional space greatly. 
Unlike the bosentan-bound system, the K-8794-bound formed only one cluster but visited the 
conformational space extensively. Similar events were exhibited in the K-8794-free (APO 
K8794) system: one conformer visited, but spanned a relatively wide conformational space.  
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Figure 4.11. Free energy landscape (FEL) plots of bosentan and K-8794 bound and APO ETB 
receptor embedded in DMPC membrane, built by two principal components (PC1 and PC2) of MD 
trajectory. The landscapes are color-coded from yellow (energy maxima) to purple (energy minima). 
 The overall analysis indicates that broadly visited conformational space over the 
simulation time suggests highly flexible systems. However, several clusters formed means 
the receptor obtained several different conformations, while one cluster indicates a formation 
of one conformation over the span of the MD simulation.  
For the purpose of understanding protein structural changes and the direction of its 
motion, the PCAs are highlighted over the protein structure as arrows (porcupine plot) 
sampled from MD simulation trajectories (200 ns to 400 ns) for ETB bound to bosentan and 
K-8794 embedded in the four membranes, were generated taking the first principal 
component mode (PC1) (Figure 4.12). The ETB experienced major movement in the ECL and 
ICL area for all of the membrane systems, as expected. The only exception is visible in the 
Bosentan-ETB-POPE system, as ICLs did not experience any major movement. A slight 
movement of the helix 8, which is the horizontal short helix in this case positioned on the 
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right, is exhibited by Bosentan-ETB-POPC, K-8794-ETB-POPC and K-8794-ETB-DMPC 
systems. The flexibility of the intra and extracellular loops is highly expected because of their 
inherent flexibility, and this also agrees with the fluctuations observed in the RMSF analysis. 
Additionally, the two bound antagonists retained the ETB receptor intact, by restraining its 
activity, as most of the intracellular loops seemed to be moving inwards. As expected, the 
secondary structure of the protein (transmembrane helices one to seven) did not experience 
any major movement and remained rigid, because the membrane phospholipid’s one of the 
main functions is to retain the integrity of the cell walls and keep the correct placement of the 
biomolecules. Furthermore, the TM helices, especially the TM6, did not demonstrate any 
outer pendulum-like motion as the lower and upper helical bundle stayed closed inwards.    
 
Figure 4.12. Porcupine plot highlighting the first PCA mode (PC1) of the bosentan (red) and K-8794 
(blue) bound ETB receptor complexes embedded in POPC, DPPC, POPE and DMPC membranes. The 
white cartoons indicate the initial secondary structure and loops before the occurrence of any 
structural changes. The purple (POPC), cyan (DPPC), green (POPE) and dark blue (DMPC) cartoons, 
representing the secondary structure and loops, indicate the finale of structural change. The black 
arrows represent the direction of motion of every Cα atom, while the length acts for the strength of the 




4.4. Dihedral Angle analysis 
 For the purpose of understanding structural rearrangements and conformational 
diversity of antagonist-bound ETB receptor, the dihedral angles of the hotspot residues 
Lys182 and Trp336 were extracted from the trajectories. The FEL representation was used to 
plot the residue angles of ligand-bound and compared with its corresponding APO ETB 
receptor structures. 
 According to Figure 4.13, in the POPC membrane the angles for φ and ψ of Lys182 
APO and the bosentan bound system did not demonstrate changes: (-70,-30). On the other 
hand, the same residue experienced changes with K-8794 bound compared to APO: backbone 
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Figure 4.13. Free energy landscape (FEL) plots of hotspot residues Lys182 and Trp336 for bosentan 
and K-8794 bound, and APO ETB receptor embedded in POPC membrane, built by two backbone 
angles φ (phi) and ψ (psi). The landscapes are color-coded from yellow (energy maxima) to blue 
(energy minima). 
 The two hotpot residue backbone angles (φ, ψ) of the ETB receptor in the DPPC 
membrane are visualised in Figure 4.14. As seen in the figure, the Lys182 backbone angles, 
when compared with APO and bosentan bound receptor, did not experience any differences 
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Figure 4.14. Free energy landscape (FEL) plots of hotspot residues Lys182 and Trp336 for bosentan 
and K-8794 bound, and APO ETB receptor embedded in DPPC membrane, built by two backbone 
angles φ (phi) and ψ (psi). The landscapes are color-coded from yellow (energy maxima) to blue 
(energy minima). 
The backbone angles (φ, ψ) of Lys182 and Trp336 of bosentan-bound and K-8794-
bound ETB receptor in the POPE membrane environment, and its APO structure is visualised 
in Figure 4.15. According to the FEL plot of Lys182 in the bosentan-bound system and APO, 
the φ and ψ angles had slight differences when comparing the system and APO: in APO 




), and in receptor in complex with bosentan 




). For the same residue but in ETB in complex with K-
8794 and APO structure demonstrated larger differences. In the K-8794-free structure, 









). Trp336 residue backbone angles in the bosentan-free and bosentan-
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), respectively. Based on the previously 
mentioned results, the ψ angle of Trp336 had a significant difference of about 15
○
. Similarly 
in K-8794-bound and Apo structure, there was a high deviation between the angles of Trp336 












Figure 4.15. Free energy landscape (FEL) plots of hotspot residues Lys182 and Trp336 for bosentan 
and K-8794 bound, and APO ETB receptor embedded in POPE membrane, built by two backbone 
angles φ (phi) and ψ (psi). The landscapes are color-coded from yellow (energy maxima) to blue 
(energy minima). 
The dihedral angle results are presented in Figure 4.16 for Lys182 and Trp336 
residues in bosentan-bound, K-8794-bound and APO ETB structures in the DMPC membrane 
environment. When comparing Lys182 φ and ψ angles in bosentan-bound and ligand-free 
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comparing backbone angles between the two structures (APO and bosentan-bound) for 



















Figure 4.16. Free energy landscape (FEL) plots of hotspot residues Lys182 and Trp336 for bosentan 
and K-8794 bound, and APO ETB receptor embedded in DMPC membrane, built by two backbone 
angles φ (phi) and ψ (psi). The landscapes are color-coded from yellow (energy maxima) to blue 
(energy minima). 





 in all membrane environments. However, higher than that of 5-10
○
 differences in angles 
were seen in Lys182 of K-8794-bound and APO structures in the DPPC environment, where 
the φ angle differs by 25
○
 between the two structures. Additionally, the 15
○
 difference of ψ 
angle between the APO and bosentan-bound structures in the POPE membrane environment 
of Trp336 residue was exhibited. Also, both the φ and ψ angles differed by 15
○
 for Trp336 
residue when comparing the K-8794-bound and ligand-free structure in POPE membrane. A 
difference of around 13
○
 in φ angle
 
was exhibited by Trp336 residue of the previously 
mentioned structures, but when they were embedded in the DMPC environment. Overall, the 
differences in angles were not that significantly large, but they were important angle changes. 
These small differences in φ (phi) and ψ (psi) angles when comparing both ligand-bound 
structures with their equivalent APO, and bosentan with K-8794 meant that both inhibitors 
maintained similar conformational orientation of the side chains of Lys182 and Trp336 




The Endothelin B (ETB) receptor belongs to a Class A G protein-coupled receptor 
family. It consists of seven α-helical bundles and loop regions facing the external and internal 
side of the membrane. ETB functions as a vasodilator and expands the blood vessels. When 
activated by ET-1 the receptor induces changes to the transmembrane helix 6 (TM6) and 
transmembrane helix 7 conformation, causing their extracellular region to move ca. 4 Å 
inwards, and the TM6 intracellular region to move outwards. The ETB receptor is involved in 
several diseases such as pulmonary arterial hypertension (PAH), hepatopulmonary syndrome 
(HPS), chronic heart failure (CHF) and many more. Therefore, several ETB receptor targeting 
drugs have been discovered. Two of them are the main targets of this study, and they are 
called bosentan and K-8794. Bosentan is the first of its kind inhibitory drug, targeting both 
the ETA and ETB receptors. K-8794 is bosetan’s high-affinity analog specific to the ETB 
receptor. When bound, both antagonistic ligands occupy the traditional orthosteric binding 
site of the ETB. 
This study has investigated the induced changes to ETB receptor during bosentan and 
K-8794 binding when the receptor-ligand complexes were embedded into four membranes of 
POPC, POPE, DMPC and DPPC. The study was carried out by a series of 400 ns long 
molecular dynamics (MD) simulations. The RMSD analysis has revealed that the last 200 ns 
of the simulations (200 ns to 400 ns) were equilibrated and used for further analysis. RMSF 
analysis revealed (as expected) that the most fluctuating parts of the ETB receptor structure 
are the extracellular and intracellular loops. The Rg analysis showed that the two ligand-
receptor complexes were relatively compact in all the membranes, but the most compact was 
K-8794-ETB in POPC and DPPC membranes. On the other hand, the least compact systems 
were the bosentan-ETB complex in POPC and the K-8794-ETB complex in the POPE 
membrane. During the H-bond analysis, the residues Lys182, Lys273, and Arg343 for both 
bosentan and K-8794 are in accordance with the fact that they form relevant H-bonds and 
contribute to the ligand binding. In addition, H-bonds established between the two ligands 
and the receptor in all of the membrane systems were 3 per average. The binding free energy 
(BFE) estimations suggested that the Lys182 and Trp336 contributed the most to the binding 
of both ligands (hotspot residues). Based on the BFE estimations, out of the four membranes, 
the most favourable membrane for bosentan binding to ETB was the DPPC membrane, while 
for K-8794 was the POPE membrane, as it exhibited the highest BFE values (highest 
minima). The least favourable was the POPC membrane for both. Out of the two ligands, the 
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more favourable established interactions with both Lys182 and Trp336 residues were of the 
K-8794 ligand. Principal component analysis (PCA) suggested that the ligand-ETB 
complexes are highly flexible systems that can visit a broad conformational space over the 
simulation time. Several clusters formed means the receptor obtained several different 
conformations, while one cluster indicates a formation of one conformation over the span of 
the MD simulation. Additionally, PCA revealed that the two inhibitors kept the ETB receptor 
intact and restrained its activity as all of the intracellular and extracellular loops were moving 
inwards, trapping the antagonist in the protein’s orthosteric binding pocket. Furthermore, the 
PCA analysis revealed that the TM6 did not experience any outer movement in its 
intracellular region, as expected when the two antagonists were bound. The dihedral angle 
analyses based on MD trajectories revealed that the dihedral angle changes of the hotspot 
residues are not large. The angles over all of the systems exhibited similarity, therefore 
bosentan and K-8794 maintained similar conformational orientation of the side chains of the 
two hotspot residues throughout the simulations while being embedded in the four 
membranes. Lastly, the study may provide theoretical knowledge and help with further drug 




The study revealed that the POPC membrane was the least favourable for a ligand 
binding to the ETB receptor, out of the four membranes analysed. Therefore, it may indicate 
that the ETB receptor favours more saturated membranes because they are less fluid and have 
higher constraining ability for a signalling protein, and the membrane can create more 
contacts with receptor helices. However, unsaturated membranes, such as POPC, can induce 
higher receptor flexibility. Hence, further studies may use saturated membranes firstly, for 
more accurate results, but it should not alienate unsaturated membrane types. But could use, 
for example, a mixture of two phospholipid types. However, it really depends on how the 
membranes of certain cell, which may be targeted, are constructed. Lastly, the ligand binding 
exploration study may provide theoretical knowledge and help with further drug development 
and discovery of ETB receptor-related medical disorders. 
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Figure A1. MODELLER script incorporating DOPE scoring per every model created. The .ali file is 
the alignment input, X-ray model sequence is the template, and the N and C-terminal truncated 









Table A1. All of the generated ETB models using MODELLER and their DOPE scores. The 
highlighted rows in grey are the final selected models based on the DOPE score and Ramachandran 
Plot evaluation in parallel. DOPE score and the models are sorted in the ascending order. 
Bosentan DOPE score K-8794 DOPE score 
ETB-orig5xpr.B99990003.pdb -40646.65234 model-ETB.B99990017.pdb -42204.51172 
ETB-orig5xpr.B99990004.pdb -40636.69922 model-ETB.B99990019.pdb -42179.47266 
ETB-orig5xpr.B99990011.pdb -40631.05859 model-ETB.B99990005.pdb -42164.35547 
ETB-orig5xpr.B99990019.pdb -40584.01562 model-ETB.B99990015.pdb -42137.91797 
ETB-orig5xpr.B99990001.pdb -40502.58203 model-ETB.B99990012.pdb -41973.42188 
ETB-orig5xpr.B99990013.pdb -40434.46875 model-ETB.B99990003.pdb -41940.69922 
ETB-orig5xpr.B99990008.pdb -40385.50781 model-ETB.B99990008.pdb -41909.19141 
ETB-orig5xpr.B99990014.pdb -40356.78125 model-ETB.B99990014.pdb -41899.94531 
ETB-orig5xpr.B99990016.pdb -40353.57031 model-ETB.B99990009.pdb -41818.85156 
ETB-orig5xpr.B99990015.pdb -40327.36719 model-ETB.B99990004.pdb -41733.78125 
ETB-orig5xpr.B99990006.pdb -40316.81641 model-ETB.B99990013.pdb -41724.01953 
ETB-orig5xpr.B99990009.pdb -40315.63281 model-ETB.B99990020.pdb -41723.10547 
ETB-orig5xpr.B99990010.pdb -40294.99609 model-ETB.B99990006.pdb -41674.69922 
ETB-orig5xpr.B99990012.pdb -40248.45312 model-ETB.B99990011.pdb -41658.35547 
ETB-orig5xpr.B99990018.pdb -40245.75781 model-ETB.B99990007.pdb -41642.03125 
ETB-orig5xpr.B99990005.pdb -40205.01953 model-ETB.B99990016.pdb -41629.85547 
ETB-orig5xpr.B99990017.pdb -40197.07422 model-ETB.B99990002.pdb -41607.02344 
ETB-orig5xpr.B99990002.pdb -40090.97656 model-ETB.B99990018.pdb -41541.39453 
ETB-orig5xpr.B99990020.pdb -40039.25000 model-ETB.B99990001.pdb -41503.75000 
ETB-orig5xpr.B99990007.pdb -39963.46484 model-ETB.B99990010.pdb -41493.09766 
 
